<SEC-DOCUMENT>0001493152-22-009991.txt : 20220415
<SEC-HEADER>0001493152-22-009991.hdr.sgml : 20220415
<ACCEPTANCE-DATETIME>20220414202029
ACCESSION NUMBER:		0001493152-22-009991
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20220412
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220415
DATE AS OF CHANGE:		20220414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39717
		FILM NUMBER:		22828751

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:LIXT="http://lixte.com/20220412">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_LIXT_lixte.com_20220412 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20220412_20220412 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001335105 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityCentralIndexKey">0001335105</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lixt-20220412.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-12to2022-04-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; width: 100%; margin-bottom: 0pt"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; margin-top: 0pt; font-size: 1pt; margin-bottom: 0pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20220412__20220412_zBsrh6WMvgW4"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURSUANT
TO SECTION 13 OR 15(d) OF THE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_902_edei--DocumentPeriodEndDate_c20220412__20220412_ze0hBYASr9Z4"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April 12, 2022</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_908_edei--EntityRegistrantName_c20220412__20220412_zg29PflZ4Kp8"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityRegistrantName">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20220412__20220412_zFMGh5oPQ8zi"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFileNumber_c20220412__20220412_zxc88zJutdsf"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityFileNumber">001-39717</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20220412__20220412_zBYcbowzNdlc"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityTaxIdentificationNumber">20-2903526</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</span></p>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20220412__20220412_z5dqRH6UAkx5"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityAddressAddressLine1">680
East Colorado Boulevard</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20220412__20220412_ziy6DpWrqQlh"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityAddressAddressLine2">Suite 180</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityAddressCityOrTown_c20220412__20220412_z8Ar8ZFKTIjh"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityAddressCityOrTown">Pasadena</ix:nonNumeric></span>,
<span id="xdx_905_edei--EntityAddressStateOrProvince_c20220412__20220412_zhHpkZzKYn84"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressPostalZipCode_c20220412__20220412_zyVElWlKeG04"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:EntityAddressPostalZipCode">91101</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--CityAreaCode_c20220412__20220412_zNGXOhmZetwi"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_90B_edei--LocalPhoneNumber_c20220412__20220412_zOwQ0btvfxli"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" name="dei:LocalPhoneNumber">830-7092</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (See General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--WrittenCommunications_c20220412__20220412_z4G0wTirkHY4"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SolicitingMaterial_c20220412__20220412_zFQqpxZFeAwb"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementTenderOffer_c20220412__20220412_z9dZltxWFKef"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20220412__20220412_zS1XQ6Z615ye"><ix:nonNumeric contextRef="From2022-04-12to2022-04-12" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--CommonStockMember_zi0FLEis1RYb"><ix:nonNumeric contextRef="From2022-04-122022-04-12_us-gaap_CommonStockMember" name="dei:Security12bTitle">Common
    Stock</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--CommonStockMember_zdJlMcQpey2b"><ix:nonNumeric contextRef="From2022-04-122022-04-12_us-gaap_CommonStockMember" name="dei:TradingSymbol">LIXT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--CommonStockMember_z9tO2fLHryD2"><ix:nonNumeric contextRef="From2022-04-122022-04-12_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market, LLC</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zyLoGeMRvScj"><ix:nonNumeric contextRef="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember" name="dei:Security12bTitle">Warrants
    to Purchase Common Stock</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zxHr5llnzj8d"><ix:nonNumeric contextRef="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember" name="dei:TradingSymbol">LIXTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zglIKJd8DHF1"><ix:nonNumeric contextRef="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market, LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; width: 100%; margin-bottom: 0pt"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; margin-top: 0pt; font-size: 1pt; margin-bottom: 0pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
1.01. Entry into a Material Agreement.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2022, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Securities Purchase
Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers named therein (the &#8220;Purchasers&#8221;), pursuant to which
the Company agreed to issue and sell, in a registered direct offering (the &#8220;Registered Offering&#8221;), 2.900,000 shares (the
&#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), at an offering
price of $2.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Offering resulted in gross proceeds of $5,800,000 before deducting the placement agent&#8217;s fees and related offering expenses.
The Shares were offered by the Company pursuant to a prospectus supplement to the Company&#8217;s effective shelf registration statement
on Form S-3 (Registration No. 333-252430), which was initially filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;)
on January 26, 2021, and was declared effective on February 5, 2021. The Registered Offering closed on April 14, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the
Purchase Agreement. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between
the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different
from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is included
with this filing only to provide investors with information regarding the terms of the transaction, and not to provide investors with
any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or
any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or
affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the
Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to the terms of the Purchase Agreement and subject to certain exceptions as set forth in the Purchase Agreement, from the date of the
Purchase Agreement until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any
agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents. In addition,
from the date of the Purchase Agreement until one hundred eighty (180) days after the Closing Date, the Company is prohibited from entering
into a Variable Rate Transaction (as defined in the Purchase Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
Agents&#8217; Fees and Expenses</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Placement Agent Agreement, dated April 12, 2022, the Company engaged WestPark Capital, Inc. and WallachBeth Capital, LLC as co-placement
agents (the &#8220;Placement Agents&#8221;) to act as the Company&#8217;s exclusive placement agents in connection with the Registered
Offering. The Company has agreed to pay the Placement Agents a cash fee equal to 7.75 % of the aggregate gross proceeds raised in the
Registered Offering, and a non-accountable expense allowance equal to 1.73%, and has agreed to reimburse the Placement Agents for their
out-of-pocket expenses including up to $75,000 for expenses of their legal counsel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued to the Placement Agents, or their designees, warrants (the &#8220;Placement Agents&#8217; Warrants&#8221;) to purchase
up to 290,000 shares of Common Stock, which represents 10% of the Shares sold in the Registered Offering. The Placement Agents&#8217;
Warrants have an exercise price of $2.00 per share, and an expiration date of April 14, 2027. The Placement Agents&#8217; Warrants and
the shares of Common Stock underlying the Placement Agents&#8217; Warrants have not been registered under the Securities Act and have
been issued in reliance on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof.
The Placement Agents&#8217; Warrants and the shares of the Company&#8217;s Common Stock underlying the Placement Agents&#8217; Warrants
may not be offered or sold in the United States in the absence of an effective registration statement or exemption from applicable registration
requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summaries of the Purchase Agreement and the Placement Agents&#8217; Warrants do not purport to be complete and are subject
to, and qualified in their entirety by, such documents attached as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form
8-K (the &#8220;Report&#8221;), and which are incorporated herein in their entirety by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
Company is filing the opinion of its counsel, TroyGould PC, relating to the legality of the issuance and sale of the Shares, as Exhibit
5.1 hereto and is incorporated by reference.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This
Report does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any
sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
3.02. Unregistered Sales of Equity Securities.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 1.01 of this Current Report on Form 8-K under the heading &#8220;Placement Agents&#8217; Fees and Expenses&#8221;
is hereby incorporated by reference into this Item 3.02 in its entirety. The Placement Agents&#8217; Warrants and the shares of Common
Stock underlying the Placement Agents&#8217; Warrants have not been registered under the Securities Act and have been issued in reliance
on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof. The Placement Agents&#8217;
Warrants and the shares of the Company&#8217;s Common Stock underlying the Placement Agents&#8217; Warrants may not be offered or sold
in the United States in the absence of an effective registration statement or exemption from applicable registration requirements. No
statement in this document or the attached exhibits is an offer to purchase or a solicitation of an offer to sell securities. No offer,
solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
8.01. Other Events.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in Item 1.01 above is hereby incorporated by reference into this Item 8.01. In connection with the Registered Offering, on
April 12, 2022, the Company issued a press release announcing the pricing of the Registered Offering, and on April 14, 2022, the Company
issued a press release announcing the closing of the Registered Offering. Copies of the press releases are filed as Exhibits 99.1 and
99.2 hereto and are incorporated by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
9.01. Financial Statements and Exhibits.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
There is filed as part of this report the exhibits listed on the accompanying Index to Exhibits, which exhibit is incorporated herein
by reference</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 14, 2022</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</span></p>

</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    JOHN S. KOVACH</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Kovach, Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO EXHIBITS</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Placement Agents&#8217; Warrant</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of TroyGould PC</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Securities Purchase Agreement</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press release dated April 12, 2022</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-2.htm">Press release dated April 14, 2022</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyFj0FOwzAQRU+QO4y8rtrEallkBxFUiBRFIQK2bjIFq4knGjuFHolb4jhEbCrVsmRZ/7//Z4RYiC096BYZ3u/KHCrs+lY5hBIPyGhq9I7s8SkF/5b4oa1jZVz4zmBGnkHPbJaJ3HshWE/aYpNCvF4l65WUEN+kcgPFTkSjnpE56AaN06oFZRoomHrW6BSfp4RKfZOh7hyqXpGtJpNCsown+QdknEh4ppP6Ij5ayPNMRItwIrFlGvqxZrCOOrhvsfNddkL/bxilDp70TfG4ma2oGLj+VBb9Xh2ZF0f1cYfdHtmbk1j63tu/IWYGHMFMwYRB4C70XE+9FPAL+Bl9yA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
  Shares: [&#9679;]</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 10pt; text-indent: -10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
  Exercise Date: [&#9679;]</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [&#9679;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on April 14, 2027
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from <B>LIXTE BIOTECHNOLOGY HOLDINGS, INC.</B>,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to [&#9679;] shares, par value $0.0001, of the Company (the &ldquo;<U>Common
Stock</U>&rdquo;) (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of
one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated April 12, 2022, among the Company and the purchasers
signatory thereto. This Warrant is being issued pursuant to the Placement Agent Agreement between the Company and WestPark Capital, Inc.
dated April 12, 2022 (the &ldquo;<U>PA Agreement</U>&rdquo;). In addition, the following terms have the meanings indicated in this Section
1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Adjustment
Right</U>&rdquo; means any right granted with respect to any securities issued in connection with, or with respect to, any issuance or
sale (or deemed issuance or sale in accordance with Section 3(b)) of Common Stock (other than rights of the type described in Section
3(d) hereof) that could result in a decrease in the net consideration received by the Company in connection with, or with respect to,
such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &ldquo;Pink Sheets&rdquo;
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Convertible
Securities</U>&rdquo; means any stock or other security (other than Options) that is at any time and under any circumstances, directly
or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Options</U>&rdquo;
means any rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &ldquo;Pink Sheets&rdquo;
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the daily
volume weighted average price of the Common Stock for such date (or the nearest preceding date), or (d) in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per Warrant Share under this Warrant shall be <B>$2.00</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
  =</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
  applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise
  is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
  pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(64)
  of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y)
  the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise, or (z) the Bid Price of the Common
  Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable
  Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
  within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading
  Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice
  of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close
  of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
  =</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
  =</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
  exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
                                            of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
                                            hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
                                            of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
                                            through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the
                                            Company is then a participant in such system and either (A) there is an effective registration
                                            statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
                                            by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by
                                            physical delivery of a certificate, registered in the Company&rsquo;s share register in the
                                            name of the Holder or its designee, for the number of Warrant Shares to which the Holder
                                            is entitled pursuant to such exercise to the address specified by the Holder in the Notice
                                            of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery
                                            to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
                                            aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the
                                            Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such
                                            date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
                                            of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
                                            of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
                                            of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
                                            Price (other than in the case of a cashless exercise) is received within the earlier of (i)
                                            two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
                                            Period following delivery of the Notice of Exercise. If the Company fails for any reason
                                            to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
                                            Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
                                            and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on
                                            the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
                                            Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages
                                            begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant
                                            Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
                                            agent that is a participant in the FAST program so long as this Warrant remains outstanding
                                            and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the
                                            standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
                                            primary Trading Market with respect to the Common Stock as in effect on the date of delivery
                                            of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of
                                            Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise
                                            Date, which may be delivered at any time after the time of execution of the Purchase Agreement,
                                            the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New
                                            York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant
                                            Share Delivery Date for purposes hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such
exercise shall be deemed rescinded) or deliver to the Holder the number of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In
and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any
other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company&rsquo;s failure to timely deliver Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Common
Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the
Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of
any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that
the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in
this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding Common Stock, a Holder may rely on the number of outstanding Common Stock
as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more
recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally
and in writing to the Holder the number of Common Stock then outstanding. In any case, the number of outstanding Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its
Affiliates or Attribution Parties since the date as of which such number of outstanding Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99 % of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon exercise
of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in Common
Stock (which, for avoidance of doubt, shall not include any Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Common
Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of
the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Common
Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number
of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to
participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Common Stock as a result of such
Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall
be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such
Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock,
(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of
the outstanding Common Stock (not including any Common Stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each
a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of
Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall
be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined
below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the
Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this
Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining
unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>,
if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors,
Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Fundamental
Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value (as defined below) of the
unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with
the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders
of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from
the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable
Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for
a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination
Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg
as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price
per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the
value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP
immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation
of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable
Fundamental Transaction and the Termination Date, (E) a 365 day annualization factor, and (F) a zero cost of borrow. The payment of the
Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&rsquo;s election
(or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the
Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior
to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Common Stock
acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to
such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but
taking into account the relative value of the Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this
Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for
(so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents
referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company
and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as
if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price or the number Warrant Shares subject to the Warrant is adjusted pursuant
to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the
Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement
of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to Form 6-K report. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Currency</U>. Unless otherwise indicated, all dollar amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S.
Dollars</U>&rdquo;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies
shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &ldquo;<U>Exchange
Rate</U>&rdquo; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar
exchange rate as published in the Wall Street Journal (NY edition) on the relevant date of calculation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section
3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares, and
in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall
not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company
will make and deliver a new Warrant or certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the PA Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal or foreign securities
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)<BR STYLE="clear: both">
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
  BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
  Kovach</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
  Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">lixte
  biotechnology holdings, inc.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="Description: TG_bw" STYLE="height: 68px; width: 240px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT="Description: test2" STYLE="height: 95px; width: 197px"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    14, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WestPark
Capital, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1900
Avenue of the Stars, Suite 310</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, CA 90067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WallachBeth
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harborside
Financial Center Plaza 5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">185
Hudson Street Suite 1410</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jersey
City NJ 07311</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lixte
  Biotechnology Holdings, Inc., Inc.</U></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Lixte Biotechnology Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection
with the Company&rsquo;s issuance and sale today of 2,900,000 shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock,
par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), pursuant to the terms of the Securities Purchase Agreement (the
&ldquo;<U>Agreement</U>&rdquo;), dated as of April 12, 2022, between the Company and the investors named therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter is being furnished to you pursuant to Section 2.2(ii) of the Agreement. Capitalized terms used and not otherwise defined in this
letter have the respective meanings ascribed to them in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">A.
<U>Reviewed Documents:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with preparing and delivering this letter, we have reviewed and relied upon originals or copies of the following (collectively,
the &ldquo;<U>Reviewed Documents</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">1.
The Agreement;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">2.
The Registration Statement;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">3.
The Preliminary Prospectus;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">4.
The Prospectus;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">5.
The Certificate of Incorporation of the Company, as amended, as in effect on the date of this letter, as certified by the Secretary of
the Company (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal"><IMG SRC="ex5-1_001.jpg" ALT="Description: TG_bw" STYLE="height: 68px; width: 240px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WestPark
                                            Capital, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WallachBeth
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Page
2 of 7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">6.
The Amended and Restated Bylaws of the Company, as in effect on the date of this letter, as certified by the Secretary of the Company
(the &ldquo;<U>Bylaws</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">7.
Copies, certified by the Secretary of the Company, of certain resolutions adopted by the Company&rsquo;s Board of Directors pertaining
to the Agreement and related matters; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">8.
Good standing certificate for the Company dated April 13, 2022 issued by the Secretary of State of the State of Delaware (the &ldquo;<U>Good
Standing Certificate</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">9.
The Notice of Effectiveness from the staff of the Commission filed on February 5,2021 on the Commission&rsquo;s Electronic Data Gathering,
Analysis and Retrieval system to the effect that the Company&rsquo;s registration statement on Form S-3 (File No. 333-252430) became
effective on February 5, 2021; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">10.
Certain corporate records of the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">11.
A certificate executed by the Chief Executive Officer and Secretary of the Company, dated the date hereof, a copy of which has been delivered
to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">B.
<U>Assumptions:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with rendering the opinions that are set forth in Section D of this letter, we have made and relied upon the following assumptions,
without any investigation or inquiry by us, and the opinions that are set forth in this letter are subject to, and qualified by, such
assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">1.
All Reviewed Documents submitted to us as originals are authentic. All copies of the Reviewed Documents examined by us conform to the
originals of such documents, and such original documents are authentic. The signatures on all Reviewed Documents are authentic. All natural
persons who have executed any of the Reviewed Documents have the legal capacity to do so. All Reviewed Documents obtained by us from
public officials are accurate, complete and authentic. There has been no fraud or forgery with respect to any of the Reviewed Documents.
All representations, warranties and other statements as to factual matters that are contained in the Reviewed Documents are accurate
and complete. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">2.
Each contract or other document (excluding the Agreement) that the Company has filed with the Commission (a) conforms to the original
of such document, (b) has been duly authorized, executed and delivered by all parties to such contract or other contract, and (c) is
enforceable by and against the respective parties to such contract or other document. The Agreement has been duly authorized, executed
and delivered by the counterparties thereto, is enforceable against such counterparties, and there are no agreements or understandings
between the parties to the Agreement that would modify the respective rights or obligations of the parties thereunder. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal"><IMG SRC="ex5-1_001.jpg" ALT="Description: TG_bw" STYLE="height: 68px; width: 240px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WestPark
                                            Capital, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WallachBeth
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Page
3 of 7</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">3.
No deletions, additions or other modifications have been made, or will be made, to the versions of the Reviewed Documents examined by
us in connection with this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">4.
There has been full compliance with all state, blue sky and foreign securities laws, rules and regulations, and, except as they relate
directly to the Company, with all rules and regulations of the Financial Industry Regulatory Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;),
that are applicable to the Agreement and the Registration Statement and the transactions contemplated thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">5.
The Agreement and certain other Reviewed Documents purport to be governed by the laws of states other than the State of California. We
are not licensed to practice law in any state other than the State of California. To the extent that the laws of any jurisdiction other
than the internal laws of the State of California, the Federal laws of the United States or the Delaware General Corporation Law (&ldquo;DGCL&rdquo;)
may bear upon or otherwise be relevant to any of our opinions or other statements expressed in this letter, we have assumed (without
rendering any opinion to such effect) that such other laws are in all respects identical to the laws of the State of California, without
regard to conflict of law provisions, and would not cause any of our opinions or other statements to be incorrect or misleading or cause
us otherwise to change or reword such opinions or other statements. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">C.
<U>Knowledge</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
an opinion or other statement set forth in this letter is qualified by &ldquo;known to us,&rdquo; &ldquo;to our knowledge&rdquo; or a
similar phrase, it means: (1) the actual knowledge (as opposed to constructive or imputed knowledge) of those lawyers who are currently
employed by our law firm and who have rendered legal services to the Company since January 1, 2020; (2) other than an inquiry of the
lawyers referred to in clause (1) and our review of the Reviewed Documents, we have not conducted any independent investigation or inquiry
to determine the accuracy of such opinion or statement; and (3) no inference as to our knowledge of any matters bearing on the accuracy
of any such opinion or statement should be drawn from the fact of our representation of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">D.
<U>Opinions:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon and subject to the foregoing and the qualifications and limitations set forth below, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">1.
The Company is a corporation validly existing and in good standing under the laws of Delaware. The Company has all requisite power and
authority, and all material governmental licenses, authorizations, consents and approvals that are required to own and operate its properties
and assets and to carry on its business as now conducted and as proposed to be conducted (all as described in the Company&rsquo;s Registration
Statement ). .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal"><IMG SRC="ex5-1_001.jpg" ALT="Description: TG_bw" STYLE="height: 68px; width: 240px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WestPark
                                            Capital, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WallachBeth
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Page
4 of 7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">2.
The Company has all requisite power and authority (i) to execute, deliver and perform the Transaction Documents, (ii) to issue, sell
and deliver the Shares and (iii) to carry out and perform its obligations under, and to consummate the transactions contemplated by,
the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">3.
All action on the part of the Company, its directors and its stockholders necessary for the authorization, execution and delivery by
the Company of the Transaction Documents, the authorization, issuance, sale and delivery of the Shares pursuant to the Agreement and
the consummation by the Company of the transactions contemplated by the Transaction Documents has been duly taken. The Transaction Documents
have been duly and validly executed and delivered by the Company and constitute the legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with their terms, except that (a) such enforceability may be limited by bankruptcy, insolvency
or other similar laws affecting the enforcement of creditors&rsquo; rights in general and (b) the remedies of specific performance and
injunctive and other forms of injunctive relief may be subject to equitable defenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">4.
The Shares which are being issued on the date hereof pursuant to the Agreement have been duly authorized and validly issued and are fully
paid and nonassessable and free of preemptive or similar rights, and have been issued in compliance with applicable securities laws,
rules and regulations. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">5.
The Registration Statement which registers the sale of the Shares to the Purchasers is currently effective, and no stop order suspending
the effectiveness of the Registration Statement under the Securities Act has been issued and, to our knowledge, no proceedings for that
purpose have been instituted or overtly threatened. Any required filing of the Prospectus Supplement pursuant to Rule 424(b) under the
Securities Act has been made in the manner and within the time required by Rule 424(b). Each of the Registration Statement, as of the
time it became effective and the Prospectus Supplement as of its date and the date hereof, complied as to form in all material respects
with the requirements of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">6.
To our knowledge, the Company has filed all reports required to be filed by it under Sections 13(a) and 15(d) of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) since January 1, 2021 (the &ldquo;SEC Reports&rdquo;). As of their respective
filing dates, the SEC Reports complied in all material respects as to form with the requirements of the Exchange Act and the rules and
regulations of the Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">7.
The execution, delivery and performance by the Company of, and the compliance by the Company with the terms of, the Transaction Documents
and the issuance, sale and delivery of the Shares pursuant to the Transaction Documents do not (a) conflict with or result in a violation
of any provision of law, rule or regulation or any rule or regulation of any Trading Market applicable to the Company or of the Certificate
of Incorporation or Bylaws of the Company, (b) conflict with, result in a breach of or constitute a default (or an event which with notice
or lapse of time or both would become a default) under, or result in or permit the termination or modification of, any material agreement,
instrument, order, writ, judgment or decree known to us to which the Company is a party or is subject that is included in the SEC Reports,
(c) result in the creation or imposition of any lien, claim or encumbrance on any of the assets or properties of the Company or (d) result
in a violation of any statute, law, rule, or regulation which, in our experience is typically applicable to transactions of the nature
contemplated by the Transaction Documents and is applicable to the Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal"><IMG SRC="ex5-1_001.jpg" ALT="Description: TG_bw" STYLE="height: 68px; width: 240px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WestPark
                                            Capital, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WallachBeth
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Page
5 of 7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">8.
In connection with the valid execution, delivery and performance by the Company of the Transaction Documents, or the offer, sale, issuance
or delivery of the Shares, or the consummation of the transactions contemplated thereby, no consent, license, permit, waiver, approval
or authorization of, or designation, declaration, registration or filing with, any court, governmental or regulatory authority, or self-regulatory
organization, is required, except for (i) the registration of the offer and sale of the Shares under the Securities Act, which has been
effected, (ii) the filing of a Notice of Listing of Additional Shares with The Nasdaq Capital Market and (iii) such consents, approvals,
authorizations, orders and registrations or filings as may be required under applicable state securities laws, as to which we express
no opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">9.
The Company is not, and after the consummation of the transactions contemplated by the Transaction Documents shall not be, an Investment
Company within the meaning of the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">10.
To our knowledge, except as described in the Registration Statement and the Prospectus, or as set forth below, there are no legal, governmental
or regulatory investigations, actions suits or proceedings pending to which the Company is or may be a party or to which any property
of the Company is or may be the subject which, individually or in the aggregate, if determined adversely to the Company, could reasonably
be expected to have a Material Adverse Effect; and to our knowledge, no such investigations, actions, suits or proceedings are threatened
or contemplated by any governmental or regulatory authority or threatened by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.15pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">E.
<U>Negative Assurance Statement:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.15pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
establishment or confirmation of factual matters or of statistical, financial or quantitative information is beyond the scope and purpose
of our professional engagement in this matter. Therefore, we are not passing upon and do not assume any responsibility for the accuracy,
completeness or fairness of the statements contained in the Registration Statement, the Preliminary Prospectus or the Prospectus, and
we have not made, or undertaken any obligation to make, any independent check or verification thereof of the accuracy, completeness or
fairness of such statements. However, we have participated in telephonic conferences with officers and other representatives of the Company,
representatives of the placement agents, counsel for the placement agents and the independent registered public accounting firm for the
Company during which telephonic conferences the contents of the Registration Statement, the Preliminary Prospectus and the Prospectus
and related matters were discussed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="Description: TG_bw" STYLE="height: 68px; width: 240px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WestPark
                                            Capital, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WallachBeth
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Page
6 of 7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely upon our participation described above, we advise you that nothing has come to our attention that caused us to believe that (i)
the Registration Statement (other than the financial statements, any notes thereto and related schedules and other financial and statistical
data contained therein or omitted therefrom, as to which we express no view or belief), as of the time it became effective, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, although we note that the Company is not currently in compliance with California Senate Bill 826 (Women on Boards)
(ii) the Prospectus (other than the financial statements, any notes thereto and related schedules and other financial and statistical
data contained therein or omitted therefrom, as to which we express no view or belief), as of its date or as of the date hereof, contained
or contains any untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or (iii) the Prospectus Supplement (other than
(x) the financial statements, any notes thereto and related schedules and other financial and statistical data contained therein or omitted
therefrom, as to which we express no view or belief), as of its date or as of the date hereof, contained or contains an untrue statement
of a material fact or omitted or omits to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading. Furthermore, based solely on our participation described above, we advise you that (1) the
Registration Statement, as of the time it became effective, and (2) the Prospectus, as of its date (in each case other than the financial
statements, any notes thereto, and supporting schedules included therein, as to which we express no view or belief), each appeared on
its face to comply as to form in all material respects with the requirements of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">F.
<U>Qualifications and Limitations:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt 0pt 2.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter and the opinions and statements that are set forth in this letter are limited by, and subject to, the following qualifications
and limitations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">1.
The only opinions that we have given in this letter are those that are expressly set forth in Section D of this letter, and no opinions
are to be inferred or may be implied beyond the opinions that are expressly set forth in Section D of this letter. The statements that
we have made in Section E of this letter should not be construed as express or implied opinions. The opinions and statements expressed
in this letter concern only the effect of laws, rules and regulations as currently in effect. We undertake no, and hereby disclaim any,
obligation to advise you of any change in any matter set forth herein, whether based on a change in laws, rules or regulations, a change
in any fact relating to the Company or any other person or entity, or any other circumstance. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal"><IMG SRC="ex5-1_001.jpg" ALT="Description: TG_bw" STYLE="height: 68px; width: 240px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WestPark
Capital, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">WallachBeth
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Page
7 of 7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">2.
We are, and are delivering this letter as, members of the State Bar of California. We neither express nor imply any opinion as to the
laws of any jurisdiction other than the internal laws of the State of California, the Delaware General Corporation Law and the Federal
laws of the United States that are generally applicable to transactions of the nature contemplated by the Agreement. We neither express
nor imply any opinion as to any other laws. The foregoing laws considered by us exclude, and we neither express nor imply any opinion
as to: (a) laws, rules and regulations of any counties, cities, towns, municipalities and special political subdivisions and any agencies
thereof; (b) any state, blue sky or foreign securities laws, rules or regulations; or (c) except as they relate directly to the Company,
any laws, rules or regulations of FINRA or the Board of Governors of the Federal Reserve System. Furthermore, we neither express nor
imply any opinion as to antitrust, banking, environmental, patent or other intellectual property, land use, tax, pension, employee benefit,
margin, usury, insolvency or fraudulent transfer laws, rules or regulations, and we do not express or imply any opinion as to compliance
by the Company&rsquo;s Board of Directors with its fiduciary duties under applicable law. We do not express or imply any opinion as to
the financial condition, results of operations or solvency of the Company. We neither express nor imply any opinion regarding compliance
with Federal, state, blue sky or foreign laws, rules and regulations that apply to misstatements or omissions made in connection with
the offer and sale of securities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">3.
Our opinion set forth in Section D(1) regarding the valid existence and good standing of the Company is based solely upon our review
of the Good Standing Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">4.
In rendering the opinion set forth in Section D(3) regarding the Company&rsquo;s execution and delivery of the Agreement, respectively,
we have not necessarily observed the execution of those documents by the Company but instead have relied exclusively upon representations
regarding the Company&rsquo;s execution and delivery of that document made in the officers&rsquo; certificate referred to in Section
A.11 and upon our review of copies, facsimiles or .pdf files of executed signature pages delivered to us by representatives of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">5.
Nothing in this letter shall be construed to cause us to be considered &ldquo;experts&rdquo; within the meaning of Section 11 of the
Securities Act. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">6.
We neither express nor imply any opinion regarding the enforceability of any provision of any Contract other than the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">7.
This letter is delivered to you solely in your capacity as placement agents in connection with the Agreement and the transactions contemplated
by the Agreement, and this letter is solely for your benefit in connection with the transactions contemplated by the Agreement. Without
our prior written consent (which may be granted or withheld in our sole discretion), neither this letter nor any portion of this letter
(a) may be relied upon by any person or entity other than you or by you for any other purpose or (b) may be quoted, assigned or delivered
to any other person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
  truly yours,</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left"><IMG SRC="ex5-1_004.jpg" ALT="" STYLE="height: 58px; width: 240px"></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: left">TROYGOULD <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PC</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of April [ ], 2022, between Lixte Biotechology Holdings,,
Inc, a corporation incorporated under the laws of the state of Delaware (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified
on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities
Act (as defined below) as to the Shares the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not
jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<SUP>nd</SUP>)
Trading Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means TroyGould PC, 1801 Century Park East, 16<SUP>th</SUP> Floor, Los Angeles, CA 90067.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers, directors, consultants or advisors
of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board
of Directors or a majority of the members of a committee of non-employee directors established for such purpose, provided that any securities
issued to consultants or advisors must be issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration
rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section
4.12(a) herein, (b) warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities
upon exercise of warrants to the Placement Agent and/or securities issued upon the exercise or exchange of or conversion of any Securities
issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding
on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted
securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance shall only be to
a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset
in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment
of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(ss).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $2.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agents</U>&rdquo; means Westpark Capital, Inc. and WallachBeth Capital, LLC, together acting as joint placement agents (each, a &ldquo;Placement
Agent&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the
Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-252430 which registers the sale of the Shares
to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sheppard
Mullin</U> means Sheppard, Mullin, Richter &amp; Hampton LLP, with offices located at 30 Rockefeller Plaza, New York, NY 10112</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below such
Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States
dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange, (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed
in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare, Inc., the current transfer agent of the Company, at its principal office in New York, New York,
and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the
execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $5,800,000.00 of Shares. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature
page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company
or its designee. The Company shall deliver to each Purchaser its respective Shares as determined pursuant to Section 2.2(a), and the
Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the
covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Sheppard Mullin or such other location
as the parties shall mutually agree. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution
of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement
Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at
the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any
additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement
Shares to such Purchaser at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such
Purchaser prior to the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that
the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to
whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such
decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such
sale, if any. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo;
(&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and
addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt
of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor
shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything to the contrary
herein and a Purchaser&rsquo;s Subscription Amount set forth on the signature pages attached hereto, the number of Shares purchased by
a Purchaser (and its Affiliates) hereunder shall not, when aggregated with all other shares of Common Stock owned by such Purchaser (and
its Affiliates) at such time, result in such Purchaser beneficially owning (as determined in accordance with Section 13(d) of the Exchange
Act) in excess of 9.9% of the then issued and outstanding Common Stock outstanding at the Closing (the &ldquo;<U>Beneficial Ownership
Maximum</U>&rdquo;), and such Purchaser&rsquo;s Subscription Amount, to the extent it would otherwise exceed the Beneficial Ownership
Maximum immediately prior to the Closing, shall be conditioned upon the issuance of Shares at the Closing to the other Purchasers signatory
hereto. To the extent that a Purchaser&rsquo;s beneficial ownership of the Shares would otherwise be deemed to exceed the Beneficial
Ownership Maximum, such Purchaser&rsquo;s Subscription Amount shall automatically be reduced as necessary in order to comply with this
paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, in a form reasonably acceptable to the Placement Agent and the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
subject to the penultimate sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to the penultimate sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer
Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
Officer&rsquo;s Certificate, in form and substance satisfactory to the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
Secretary&rsquo;s Certificate, in form and substance satisfactory to the Purchasers; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the
Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the
corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and
all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and
free of preemptive and similar rights to subscribe for or purchase securities. There are no outstanding options, warrants, scrip rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into
or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any capital stock of any Subsidiary,
or contracts, commitments, understandings or arrangements by which any Subsidiary is or may become bound to issue capital stock. If the
Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s)
to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby, and (iv)
the filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively,
the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable
pursuant to this Agreement. The Company has prepared and filed with the Commission a registration statement under the Securities Act
on Form S-3 (File No. 333-252430) on January 26, 2021, providing for the offer and sale, from time to time, of up to $20,000,000 of the
Company&rsquo;s securities (the &ldquo;<U>Registration Statement</U>&rdquo;). The Registration Statement became effective pursuant to
Rule 467(a) under the Securities Act on February 5, 2021 (the &ldquo;<U>Effective Date</U>&rdquo;). The prospectus included in the Registration
Statement at the time it became effective, including documents incorporated therein by reference, is referred to herein as the &ldquo;Base
Prospectus&rdquo;. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness
of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings
for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required
by the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At
the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date,
the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the
Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary to make the statements therein not misleading; and the Prospectus, the Prospectus Supplement and any amendments
or supplements thereto, at the time the Prospectus, the Prospectus Supplement or any amendment or supplement thereto was issued and at
the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will
not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration
Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements
with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) calendar months
prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
&ldquo;issuer free writing prospectus&rdquo; (as defined in Rule 433 under the Securities Act) relating to the Shares is hereafter referred
to as an &ldquo;<U>Issuer Free Writing Prospectus</U>&rdquo;. Any reference herein to the Base Prospectus and the Prospectus shall be
deemed to refer to and include the documents incorporated by reference therein as of the date of filing thereof; and any reference herein
to any &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to any of the Base Prospectus and the Prospectus shall be deemed
to refer to and include (i) the filing of any document with the Commission incorporated or deemed to be incorporated therein by reference
after the date of filing of such Base Prospectus or Prospectus and (ii) any such document so filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Base Prospectus, or the Prospectus, or any Issuer Free Writing Prospectus,
or any amendments or supplements to any of the foregoing, shall be deemed to include any copy thereof filed with the Commission on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed the registration statement with FINRA or meets the definition of an Eligible Issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule
3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as
of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act,
other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of
Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as a result of the purchase and sale of the Securities, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the
capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance
and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any
Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision
that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company
or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or
similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or
&ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the
Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state
securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for
the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect
to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the
Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no
event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed
made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)
adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)
could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of
the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other
than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities
Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which
the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue
to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer
through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to
the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For
the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess
of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due
under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to
any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth on <U>Schedule 3.1(dd)</U> of the Disclosure Schedules. To the knowledge
and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall
express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year
ending December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage
in hedging activities at various times during the period that the Securities are outstanding, and (z) such hedging activities (if any)
could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities
are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction
Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent in connection
with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any
Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company
and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Other Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
Reserved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Regulatory</U>. Except as described in the Registration Statement and the Prospectus, as applicable, the Company and its Subsidiaries
(i) are and at all times have been in material compliance with all statutes, rules and regulations applicable to the ownership, testing,
development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale,
storage, import, export or disposal of any product manufactured or distributed by the Company including, without limitation the Federal
Food, Drug and Cosmetic Act (21 U.S.C. &sect;301 et seq.), the federal Anti-Kickback Statute (42 U.S.C. &sect;1320a-7b(b)), the Health
Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009, and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Affordability Reconciliation
Act of 2010, the regulations promulgated pursuant to such laws, and any successor government programs and comparable state laws, regulations
relating to Good Clinical Practices and Good Laboratory Practices and all other local, state, federal, national, supranational and foreign
laws, manual provisions, policies and administrative guidance relating to the regulation of the Company (collectively, the <I>&ldquo;</I><U>Applicable
Laws</U><I>&rdquo;</I>); (ii) have not received any notice from any court or arbitrator or governmental or regulatory authority or third
party alleging or asserting noncompliance with any Applicable Laws or any licenses, exemptions, certificates, approvals, clearances,
authorizations, permits, registrations and supplements or amendments thereto required by any such Applicable Laws (<I>&ldquo;</I><U>Authorizations</U><I>&rdquo;</I>);
(iii) possess all material Authorizations and such Authorizations are valid and in full force and effect and are not in violation of
any term of any such Authorizations; (iv) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging
that any product operation or activity is in violation of any Applicable Laws or Authorizations nor is any such claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action threatened which (A) contests the licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any products of the Company, (B) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Company product, (C) imposes a clinical hold
on any clinical investigation by the Company or any of its Subsidiaries, (D) enjoins production at any facility of the Company or any
of its Subsidiaries, (E) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries,
or (F) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either
individually or in the aggregate, would have a Material Adverse Effect; (v) have not received any written notice that any court or arbitrator
or governmental or regulatory authority has taken, is taking or intends to take, action to limit, suspend, materially modify or revoke
any Authorizations nor is any such limitation, suspension, modification or revocation threatened; (vi) have filed, obtained, maintained
or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were complete and accurate on the date filed (or were corrected or supplemented by a subsequent
submission); and (vii) are not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders,
or similar agreements with or imposed by any governmental or regulatory authority. The Company has not been informed by the United States
Food and Drug Administration (&ldquo;FDA&rdquo;) that the FDA will prohibit the marketing, sale, license or use in the United States
of any product produced or marketed by the Company nor has the FDA halted any approved investigational device exemption, clinical program
or other trial of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>Material Agreements</U>. The agreements and documents described in the Registration Statement or Prospectus conform in all material
respects to the descriptions thereof contained or incorporated by reference therein conformed in all material respects to the requirements
of the Securities Act or the Exchange Act, as applicable at the time filed, and were filed on a timely basis with the Commission and
none of such documents contained an untrue statement of a material fact or omitted to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; any further documents so filed and there are no
agreements or other documents required by the Securities Act and the rules and regulations thereunder to be described in the Prospectus
or to be filed with the Commission as exhibits to the Registration Statement or to be incorporated by reference in the Registration Statement
or Prospectus, that have not been so described or filed or incorporated by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>Compliance with Healthcare Laws.</U> The tests, studies, and trials conducted by or on behalf of or sponsored by the Company or any
of its subsidiaries were and, if still pending, are being conducted in all material respects in accordance with all applicable Health
Care Laws (as defined below) and standard medical and scientific research protocols, procedures, and controls; none of the Company or
any of its subsidiaries has received any written notice, correspondence, or other written communication from any regulatory agency or
any institutional review board or comparable body requiring or threatening the termination, suspension, or material modification of any
tests, studies, or trials, or commercial distribution, and to the knowledge of the Company and its subsidiaries, there are no reasonable
grounds for the same. Each of the Company and its Subsidiaries has obtained (or caused to be obtained) the informed consent of each human
subject who participated in a test, study, or trial. None of the tests, studies, or trials involved any investigator who has been disqualified
as a clinical investigator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its directors, officers, employees, and agents are, and at all times prior hereto have been, in material compliance with,
all health care laws and regulations applicable to the Company or any of its product candidates or activities, including development
and testing of pharmaceutical products, kickbacks, recordkeeping, documentation requirements, the hiring of employees (to the extent
governed by Health Care Laws), quality, safety, privacy, security, licensure, accreditation or any other aspect of developing and testing
health care or pharmaceutical products (collectively, <I>&ldquo;</I><U>Health Care Laws</U><I>&rdquo;</I>). The Company has not received
any notification, correspondence or any other written or oral communication, including notification of any pending or threatened claim,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental authority, including, without
limitation, the United States Food and Drug Administration, the Drug Enforcement Agency, the Centers for Medicare &amp; Medicaid Services,
and the U.S. Department of Health and Human Services Office of Inspector General, of potential or actual non-compliance by, or liability
of, the Company under any Health Care Laws. To the Company&rsquo;s knowledge, there are no facts or circumstances that would reasonably
be expected to give rise to liability of the Company under any Health Care Laws, except that would not individually or in the aggregate
have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, it will be an
&ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Prospectus, Prospectus Supplement,
Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to
ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and
conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about
the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it
to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such
Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser
with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement
Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent
and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided
to it. In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has
acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Legends</U>. The Shares shall be issued free of legends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
Reserved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would
be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would
require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing
of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the
transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges
and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company,
any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the
Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other
in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall
issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any
press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which
consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party
shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the
Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities
law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required
by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted
under this clause (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information
and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its
Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information
to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any
duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or
Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law.
To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities as set forth in the Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or
any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such
Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct)
or (c) the Company will indemnify each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all
losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred,
arising out of or relating to (i) any untrue or alleged untrue statement of a material fact contained in such registration statement,
any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of
or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading,
except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such
Purchaser Party furnished in writing to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in
connection therewith. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant
to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume
the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the
right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel
shall be at the expense of such Purchaser Party except to the extent that (x) the employment thereof has been specifically authorized
by the Company in writing, (y) the Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position
of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses
of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement
by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed;
or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach
of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in
addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company
may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all
of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market. The Company further
agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application
all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted on such other Trading
Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its
Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under
the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (ii) file any registration
statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in
connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until 180 days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement
to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units
thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company
(i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to
receive additional Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or
varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities,
or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business
of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but
not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price. Any Purchaser shall
be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right
to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered
to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser
by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included
in the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary,
the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will
not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Capital Changes</U>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock
split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the
Shares, except as may be required in connection with the satisfaction of the minimum bid price requirement of the principal Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.
In addition to the Transaction Expenses, the Company shall be responsible for the payment of any placement agent&rsquo;s fees, financial
advisory fees, transfer agent fees, Depositary Fees, DTC fees or broker&rsquo;s commissions (other than for Persons engaged by any Purchaser)
relating to or arising out of the transactions contemplated hereby (including, without limitation, (x) any fees or commissions payable
to the Placement Agent, who is the Company&rsquo;s sole placement agent in connection with the transactions contemplated by this Agreement
and (y) any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), and any stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to the Purchasers.
The Company shall pay, and hold each Purchaser harmless against, any liability, loss or expense (including, without limitation, reasonable
attorneys&rsquo; fees and out-of-pocket expenses) arising in connection with any claim relating to any such payment. Except as otherwise
set forth in this Agreement, each party to this Agreement shall bear its own expenses in connection with the sale of the Shares to the
Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached
hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the
signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c)
the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service
or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document
constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on
the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by
the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately
and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the
benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature
page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through Schiff Hardin. Schiff Hardin does not represent any of the Purchasers and only represents the Placement
Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company
and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision
contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the
Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy to (which shall not constitute notice):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">LIXT </FONT>SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:_________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)
the Closing shall occur on the second (2<SUP>nd</SUP>) Trading Day following the date of this Agreement and (iii) any condition to Closing
contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed
of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead
be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate
or the like or purchase price (as applicable) to such other party on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; padding: 0; text-align: justify; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PASADENA,
CA, April 12, 2022 &mdash; LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically
active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purchase and sale of
2,900,000 shares of LIXTE&rsquo;s common stock, at a purchase price of $2.00 per share, in a registered direct offering. The closing
of the offering is expected to occur on or about April 14, 2022, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WestPark
Capital, Inc. and WallachBeth Capital, LLC are acting as co-placement agents for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to LIXTE from this offering are expected to be approximately $5.8 million before deducting the placement agents&rsquo;
fees and other offering expenses payable by LIXTE. The company intends to use the net proceeds from the offering for working capital
and general expenses including further development of its lead clinical compound LB-100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock are being offered by Lixte pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-252430)
previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on January 26, 2021 and declared effective by the
SEC on February 5, 2021. The offering of the securities will be made only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities
being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained,
when available, on the SEC&rsquo;s website at <U>http://www.sec.gov</U> or from: WestPark Capital, Inc. - Attention: Jason Stern, 1900
Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077 or by Email: <B><U>syndicate@wpcapital.com</U></B> or by telephone at (310) 203-2919.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LIXTE Biotechnology Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
Biotechnology Holdings, Inc. (Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development
and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways
in cells on or off. Most cancer research over the past 30 years has focused on the &ldquo;on&rdquo; switches because the &ldquo;off&rdquo;
switches, especially the master &ldquo;off&rdquo; switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients.
LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, demonstrating that
LB-100 is readily tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical
data (see www.lixte.com), LB<B>-</B>100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies
or immunotherapies. LIXTE&rsquo;s new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept
clinical trials are in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company&rsquo;s financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing,
costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as
&ldquo;intend,&rdquo; anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;potential(ly),&rdquo; &ldquo;continue,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;predict,&rdquo; &ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo;
&ldquo;should,&rdquo; &ldquo;expect&rdquo; or the negative of such terms or other comparable terminology. The Company believes that the
assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the
date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that
the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently
subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated
in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory
policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company&rsquo;s filings with the United States Securities and Exchange Commission at
<U>http://www.sec.gov/edgar.shtml</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lixte
Contact:</B><BR>
<U>info@lixte.com</U><BR>
General Phone: (631) 830-7092<BR>
Investor Phone: (888) 289-5533</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; padding: 0; text-align: justify; text-indent: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PASADENA,
CA, April 14, 2022 &mdash; LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically
active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional
and accredited investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock at a purchase
price of $2.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WestPark
Capital, Inc. and WallachBeth Capital, LLC acted as co-placement agents for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to LIXTE from this offering were $5.8 million before deducting the placement agents&rsquo; fees and expenses, and other
offering expenses payable by LIXTE. The Company intends to use the net proceeds from the offering for working capital and general corporate
expenses, including further clinical development of the Company&rsquo;s lead compound LB-100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock were offered by LIXTE pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-252430)
previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on January 26, 2021 and declared effective by the
SEC on February 5, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus supplement and accompanying prospectus relating to the securities offered have been filed with the SEC. Electronic copies
of the prospectus supplement and accompanying prospectus may be obtained on the SEC&rsquo;s website at http://www.sec.gov; or from: WestPark
Capital, Inc. - Attention: Jason Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077; or by Email: syndicate@wpcapital.com;
or by telephone at (310) 203-2919.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LIXTE Biotechnology Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
Biotechnology Holdings, Inc. (Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development
and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways
in cells on or off. Most cancer research over the past 30 years has focused on the &ldquo;on&rdquo; switches because the &ldquo;off&rdquo;
switches, especially the master &ldquo;off&rdquo; switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients.
LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, demonstrating that
LB-100 is readily tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical
data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or
immunotherapies. LIXTE&rsquo;s new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept
clinical trials are in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company&rsquo;s financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing,
costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as
&ldquo;intend,&rdquo; anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;potential(ly),&rdquo; &ldquo;continue,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;predict,&rdquo; &ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo;
&ldquo;should,&rdquo; &ldquo;expect&rdquo; or the negative of such terms or other comparable terminology. The Company believes that the
assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the
date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that
the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently
subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated
in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory
policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company&rsquo;s filings with the United States Securities and Exchange Commission at
<U>http://www.sec.gov/edgar.shtm</U>l.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FCFCFC"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lixte
Contact:</B><BR>
<U>info@lixte.com</U><BR>
General Phone: (631) 830-7092<BR>
Investor Phone: (888) 289-5533</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ / # 2(  A$! Q$!_\0
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M&4B,'ER%S0!)15"VN6G1I#-$0)#&Z(87DMI_,Q)97#P37$+7%JW^CR*A&Y^
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M*@@'!'<'/\617Y3_ /!"I0O[6/C4 8$GPM._DY.?$]MD@YRIYZJ1CM7ZK?\
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MOTN_99^%-O'HUGJ%]IL+_:?L4\<<BMY<8M5C6V98<B%3:QJGV8J@,!56BVL
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M+RW/F16LEJCAY6<R.T$C1RK*72\!"W:S* *_BE_X*]?\&^.J>,?&7BG]H?\
M8PL-&M/%&O7EWK?C/X SW/\ 8NA>*KI;*9+_ ,0?#;4]0>[T[P_*(&F?4=$U
M9&L;J\<S65@LY5Z /Z[OV=?%]EKGA32FAN#-#/IFD7%A>QM;R0:S875M'?6V
ML:>\"F.2SG@=8I0#F/[R[7!-?3_F HSH"Y4$A1C+$ D*.V21@9[]>*_SH?\
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M9/*+&,1E(US&%$>[<^W>[LR^1&-N-ZA(S$JK+*B!",<(KA-X'"R;?,4<*XH
M\'\!_ OPK\/;3XKQ:)JGBN.W^,GQ+\:_%'Q5?RZS=V&JV>N>/M$T_P /ZJGA
MW4],:TU31;>WATK2Y]->*: Z3/96U[9-!<6\<\?'? K]F+1/@MXT\7_$:[^(
M'Q&^)_CWQGX;\(_#^;Q=\4;[PM<ZU;^ ? FH:_J'A3PXEWX:\/:)=>)+ZQNO
M%&L2:AXT\8R:[X]\4>;8_P#"4>)]872=+%I]5"*,/Y@0>9T+_P 9']TM]XKZ
M*25&!@<##@JABV/F(QN/)QG. 3R!GG XSVH =1UHHH ;L7T_4_XT;5]/U/\
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:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_002.jpg
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? ,4# 2(  A$! Q$!_\0
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M(H].M=#C@DABDLXY(WWQ%R'8_,!D'D'O[5V/@[79/$WA'2]9F@$$MW '>,=
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MNY666;S,YV <'&,?4UI_\)CH/V=I_MK;5F6#9Y$GF%V!90$V[CE02"!@@$T
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M@9S72^']7N[^34+'4H((M1T^98IOL[%HW#('5ER,]&Q@]P: -NBBB@ HHHH
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MR@HQ]WLV1W'I0!9'C'0FLDNQ=R&*1_+C'V:7?(=N[Y%V[F&.<@$8I)O&?AZ
M1,^IQ[)8DF5U1F4(Y*JQ8#"@L".<<\56_P"$7U I9RMX@F:_LMRV]R;6/B-E
M 9&7HV=JG/'(_"HT\"6D=C<6JWMP1<10I([!2Q9)FF+^F69SD=!VH W]-U2S
MU:V:XLI3(BR-&^4*,CCJI5@"#]15RJ.FZ8FFR7[I(SF\NFN6W#[I*JN![?+5
<Z@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex5-1_004.jpg
<TEXT>
begin 644 ex5-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ /0# 2(  A$! Q$!_\0
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MU]0\$^(?AXFK02^)8]2\0W.GZG;W>DW>L>(-=O+S3[AKJW6T^??^"9?[$_\
MP3:\>_M2?\%,?V=O$G_!,[]A&UU+]B+]I3PSX"^'?B./X4/\4KO6OA/\3/!.
MG>.? D_BT_'/5/B5-'\2M'ET#54UC7/#+Z!HD*7*Z/HFA:7_ &?K%WXA /J_
M7?\ @Y6_X(XZ==OI/A;]J36_BUXC\NWN8_#GPA_9\_:,\<W[VD\<[M<#4-.^
M%@\/ 6R6MS=75O+K4%_#9QFX^Q/$HEDP)_\ @O;;^*'U.Q^!?_!)S_@L7\:+
MJ,7D'A_Q3#^Q=J'P_P#A/KFI:=:F^N[&[\>>+O&,>I>')/LZ/% -4\&F6349
M;2R\H17!O8_W/\(?#_P-\/=(/A_P#X/\,>!]!-W/J!T3P=H&D^&-'-_=O')>
M7YTK1+.QT_[?=O$C7-[]F^URLJEILHFWJS$A.3G()P>A4%0I",H#(#C)VD9)
M.>#B@#^:_6/^"P?_  5[UB?[=\+/^#>+X^ZEX4>ZM#9WWQ._:G\!_#/QA=P6
MYC37++4? =_\+;V?0;I[E+V'1-1AU[Q#9WEE'9:K]FEEN;O2--OZ3_P6$_X*
MTZ?J4<GQ(_X-V_VC-$\+K!?27>I?#;]K+X9_%KQ+%-;6[RP6]IX3M/A7X66^
M,\JB.1AKMM<1;ML-G=RA8G_H_%O& 1R<ILRVTD*69V4,5W;&8C,6?)"JJ+&J
M J7&,8(W.!C^^QP 23R26.X<')X ^7:>: /PU^&7_!?[]CW4O'G@?X1_M3_#
M3]J__@G7\5OB+JL'AGP5X<_;G_9Y\7_!_P ->,/$_P#H$5W:>&/B=9MXE^'3
MZ,MW?Q16?B+Q3XC\(Z7=6\NGW#RP2:QIEK<?N0DC$@$*<N8\H690RB0L-VT
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M$NH1ZU#HFGQ_&;0?#T<VGZDD<MOHN_1]2M/#M_"OV75;;3I5LS+IUO8W,O\
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MRI_P3W_X*0?%K1/V?O"*?$_X$?'#Q+:ZC)X6\%?'32O".C:5XWO]-A6[?0O
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M?^*?%6E> ?#T=DU]?>*/%=YKWBCQMXE>VT;P3I&N:_+'J6LZ?=:GI4=_T/\
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M]G_QM^VA\0&\%>&/A-\#]6^,GC^[\0/?ZY#\+/!_Q-\4ZU\1_!WPC\/00?\
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M\*ZW>0>%?AE=:OI%I+<^')%O/#/]GW;V/@RX\8^([31_C'HOFOQ6_9Q^&/\
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MUN;5=-@M_*UJ^U[S)&U_4M7-]J&O2222:O=7KR.S '^9-\9]!\-?L@_L=?\
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>lixt-20220412.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSBmbP9z5Z8yekhvWB2bZlaryssN4TKZSWrnn1GQQwI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:LIXT="http://lixte.com/20220412" elementFormDefault="qualified" targetNamespace="http://lixte.com/20220412">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lixte.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lixt-20220412_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lixt-20220412_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lixt-20220412_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="LIXT_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>lixt-20220412_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20220412.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20220412.xsd#LIXT_WarrantsToPurchaseCommonStockMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>lixt-20220412_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20220412.xsd#LIXT_WarrantsToPurchaseCommonStockMember" xlink:label="LIXT_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>lixt-20220412_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20220412.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20220412.xsd#LIXT_WarrantsToPurchaseCommonStockMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139660148766552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 12,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001335105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2903526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680
East Colorado Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">830-7092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to Purchase Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXTW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LIXT="http://lixte.com/20220412"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lixt-20220412.xsd" xlink:type="simple"/>
    <context id="From2022-04-12to2022-04-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-12to2022-04-12">0001335105</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-12to2022-04-12">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-04-12to2022-04-12">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-12to2022-04-12">2022-04-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-04-12to2022-04-12">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-04-12to2022-04-12">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-04-12to2022-04-12">001-39717</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-04-12to2022-04-12">20-2903526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-12to2022-04-12">680 East Colorado Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-04-12to2022-04-12">Suite 180</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-12to2022-04-12">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-04-12to2022-04-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-12to2022-04-12">91101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-04-12to2022-04-12">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-04-12to2022-04-12">830-7092</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-04-12to2022-04-12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-04-12to2022-04-12">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-04-12to2022-04-12">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-04-12to2022-04-12">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-04-122022-04-12_us-gaap_CommonStockMember">Common     Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-122022-04-12_us-gaap_CommonStockMember">LIXT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-122022-04-12_us-gaap_CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember">Warrants     to Purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember">LIXTW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-122022-04-12_custom_WarrantsToPurchaseCommonStockMember">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (VBCE0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "-HHY4-2BI^NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)VW50^CFHGA2$%Q0O(5D=C?8_"$9:??M3>MN%]$'$'+)S"_?
M? /I=10Z)'Q.(6(BB_EJ<H//0L<-.Q!% 9#U 9W*=4GXTMR%Y!25:]I#5/I#
M[1%:SF_!(2FC2,$,K.)*9+(W6NB$BD(ZX8U>\?$S#0O,:, !'7K*T-0-,#E/
MC,=IZ.$"F&&$R>7O IJ5N%3_Q"X=8*?DE.V:&L>Q'KLE5W9HX.WI\659M[(^
MD_(:RZML!1TC;MAY\FMW=[]]8++E;5OQZZJYV7(NVG*Z]]GUA]]%V 5C=_8?
M&Y\%90^__H7\ E!+ P04    " "-HHY4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M (VBCE2$93N#=P0  ',2   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9C;<N(X$(:O)T^AXFJF*@F6"*<I0A4A9$)- FQ@-WNHO1"V %5LBY'DD+S]
MM@S8;-:TV<E%\*E_?U*W_U:ILU'ZQ:R$L.0M"F-S75E9N_Y:K1I_)2)N+M5:
MQ'!GH73$+9SJ9=6LM>!!&A2%5>9YC6K$95SI=M)K$]WMJ,2&,A8334P215R_
MWXA0;:XKM+*_\"27*^LN5+N=-5^*J;"_KB<:SJJ92B C$1NI8J+%XKK2HU]O
M6,L%I$_\)L7&'!P3-Y2Y4B_N9!A<5SQ')$+A6R?!X>=5]$48.B7@^+$3K63O
M=(&'QWOUNW3P,)@Y-Z*OPF<9V-5UI54A@5CP)+1/:G,O=@.J.SU?A2;]3S;;
M9Z^N*L1/C%71+A@((AEO?_G;;B(. FJM(P%L%\!2[NV+4LI;;GFWH]6&:/<T
MJ+F#=*AI-,#)V&5E:C7<E1!GNWWU*G2G:D'*7:CZN[";;1@[$M9;ZTM"V3EA
M'F/_#J\"08;!,@R6ZM6.Z-TJ/X%<6S)[7XLB'#R\=?$=@:AE$#54I0<$04IQ
M%_)E$04>O^"A$0C'5<9Q==ID3(26*B"#.""0W,)YP97V:3K[]*DD4?6,K8XJ
M#F(K[3NYDZ$@HR2:%Q</KN%Y]*+6;M(FPM/(>!JG\#R)I316<YBT$8\*9PK7
M>1C^/AN<W0S'LT'_?C1^&'_[@]R/'VZ'HV_3<S(<]2\1V&8&VSP%M@^YU3PD
MPS@0;^2[>"_"Q94\F,-:K4Z].H+5RK!:IV#-^!L9!L F%]+GJ6<>SS"NR+P+
MUO9J==9 \-H97OL4O&'L*[U6.B4[)U,+7P11FO15 M,)LZJ"PKSCXK<#A)!Z
MN8MZIS#V@D +8\[W!^0!GB/CN!"L1++1\LX&W%@86 BC#A2Y44DH7KD.,.0#
MXZ<_CSS;J$)D7'*:2,@);7D88-X2*&[J'P'[[@P2/E.;N! .EYMPPZ&Z.<:6
M=PJ*6_U'MJP:)UJ]RM@O3CBNV>]A:'GSH+CG?T2;*&/!;/Z4ZZ.?2(EBFU*/
M8FQY\Z"X\Z<I[,'J\3@*+O"Y4:-?,)2\;] 2PU<^S,IDI6*LD96(M&K>1=-K
M8XV5YLV!XI[^K*6U(H:IB:(DWEFP*:3"A<K6(31O#!3W\:D*I2^MC)?D$0I<
M2QX6\N JI3QY)Z"X6T^TN/!A>@1\8=OE(JS8A";CQ>)(_G"],C*6-P"&N_5_
MR(;&)$!6!E@B6PJ8VSW#O=E5%73TJ57^"_GK4;B*_QM3/EBZX\8ZDQ86@VH!
M"\W/\R]D*OP$*KEP45.BM&4\(_"7<F)XN54SW%9GT#M= 4_?H[DJ+-\2 ;<T
MQ$AR9V:XC^YGA@S>_!6/E^+H6K5$:-2;WO9^P9AR1V:XH3YS[5;-AEA%)HD&
M+B/(8:U@;\G-EN$^^7]*!%?:\Z9%\C/,N1TSW$5/J!M<P-7-,X:2VS KL>'3
M"P<7.EXXU8,M!+<=\\CU4L:&A&(!2MYE$\I(;W<XMB=6K=-=A;FR5D7IX4K
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M',$8  <,2=/^/7CW/DK&]U1R^8^P^0E02P,$%     @ C:*.5)>*NQS
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M7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ C:*.5"0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "-HHY4-2BI^NX    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "-
MHHY4F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( (VBCE2$93N#=P0  ',2   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "-
MHHY4X/0ZB:H"   P#   #0              @ &Z#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( (VBCE27BKL<P    !,"   +              "  8\/
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (VBCE2JQ"(6,P$  "("   /
M          "  7@0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "-HHY4
M)!Z;HJT   #X 0  &@              @ '8$0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "-HHY499!YDAD!  #/ P  $P
M        @ &]$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(   '%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex4-1.htm</File>
    <File>ex5-1.htm</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
    <File>lixt-20220412.xsd</File>
    <File>lixt-20220412_def.xml</File>
    <File>lixt-20220412_lab.xml</File>
    <File>lixt-20220412_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "lixt-20220412_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lixt-20220412_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lixt-20220412_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lixt-20220412.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 1,
   "memberStandard": 1,
   "nsprefix": "LIXT",
   "nsuri": "http://lixte.com/20220412",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-04-12to2022-04-12",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://lixte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-04-12to2022-04-12",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "LIXT_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://lixte.com/20220412",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001493152-22-009991-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-009991-xbrl.zip
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MCQK687/LPZ &-P?^J+<O8G*095V0%,:P$;R.5EP1)11H$C68PC=)Z/*K(K8
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MA,@?8>+@LK2%=OS+6(I0ZY2S3K01A5>9,1V5,'G$D%NGB51*@/T%PVZRG.<
MQT6]*1(AH;"%X-P'^-,5:>!SF955LH!.(Z$WJK9(&LJ"BA@YJK ;B<@RJ<B
M'$3$Z^W0Z4SDR^HQ*?+D?$ ].;:;W25C&#B<LX4D[W=C@3$T]1Z&E#51MEI7
MR*'!&&@:$?0CJVT2AZ.+Z* __H[ZTP<1>@N,[Y,#QO=N,;Y/#AC? \;WLPGY
M_]4LAYKF\.+\[<7YY?F;=V?O7OW\YI+8#G\]N[@X>_/NU?GEOHWS'@$R'@GG
MX<6 !^[7;1XX9D8\_X IF2%AG^@*+[(ZA>L;>5)LL9+:(H&&OK,*I^>!2(C
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M3@1<:+CDX?[/2\Z_D.H /4V/E<'@8Y7!LZ4V6:DHXK.FHZ$I!Z%E@A^/)J"
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M)5:A2L:]+:F1&-9"$P]&VGB$A A2#W%*"*<MU ?$,,3;P6%BR9':KN#R(/\
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M?G$[$;&-8?E&FINPSUW=A'4/GJ7;X*]D&M'&KPWC5.=M8[V7"'V2"JKQ-E8
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M(* NW>+!^QTJ'*_LC H[N1'RS+AZ)2KE*$^NB6-P<'[=A#H;:L?0E>LD?4]
MT,&K@ZX+D#H@^>4U#GCCZL-:(B_+Z.^2MS%0SU#IM8 R< H[+<9!YVK)R1(6
M.5]RS/\J+1D6VK!"1XT0Z5C0#*YHS),AZ?P*H"'AR*( ]=E+(P7RTA4^AJ@;
M\!;L0NA<LEQ0KA-N/B;H6 L1QD',?>(XX>-#G/".XX2/#W'"0YQP#Z7%W2E%
MA#=&&O_-%''7;*^P/@3J"B:PO)/*-_Z:=&:-M=/M]80Z=U6N,M;,R9JQ!*2E
MMF>ZESS[,,<C#T_S3&F:#,JDRZ+,R\5&G&ZK=8LN#"XGARGAIKDNJ_<UXA&K
M&6+3X(XNYPW_"W2%1*=0BHZ3V.PM'^\:C[BR-&6OJ'*J-?) 9?3I%6>0N-A:
ML\RJF91TI49MH;9AVJ6LP<R4W]ML;3WP:G 3FVB"#DRP5%6Z$:PZ#Y9>_ )>
MI,LWL5JX"3(]73BJ7^2,O7JTI@W7U[(9C -9:VPPFROIKL_R5;D!MP#[QZ%A
MO&,'B=4?#GD\PC$_[>6S#H^2ZX5;!^D6=M502>7"9I@-8:L2XS._M1QW(8L8
M76VQ+CBFRRZ*X8YI/S1/237-D&:7@\(!=I_.!_T2.4X=9CSVI9=(#;6D@+9&
M+^KS*@>+M$1WR,0%<84<#?@C[8$8V#S6O<(_LZR9C@AWZ!<4)FD+6P20$T?1
MG4(U!V,D1/+U^:RCI)PYPF*7D 5;[.,S2I)H2Z;(4YUU>_/6SU9"Z":YANJT
M8CH@VE+4$U6#L$[F!I/(.,_ UV'DK&&<.JZ1YI(%B T.Y797,[?=8E('6G*A
M D;_,M9 EIE"[V^!EF)_,7%7#BS/4^_(5Q/!6,B;9P(MJG;->1ZPC+645,!-
MN]$"BBP_^+:07#!8/)"7%5;3A=_2%/&T"*#]8#CLP: FO_W&JL#/E)9"^&O!
ML)\Q28"4SOV8] 3\*-[F>7/7"U\*KH2UJL$MM794Y6T7<;HYR2$DOU8U+_"Q
M7XXOC^%,%[9^ZVR5%1;UR_Z>\>BFF; ]H+;>H:QHX:TOL,HK5\Z8^*O[YY=G
MSX-2B_=L^]S/,_'^/9\)6N$+K%C_UA:I_[',9UQ0VK$:;RMEXW4J@R%1TKD2
MWC658>H=;G,I;6JF9,[!YXM-59FQY$E??_.5+SHC>L,%JFDM]F)FN&++UU_J
MBBT^!2TL.U.7MAYGU*[1.=K%EC!AOJF;P^[=@T%-\IQW[S,L2^;WJZOF<[,D
M%].HZR[T/%PJ>]6*^:&WN7HO)]\\";9B-,&?>#'Y[,?G9SV3ALL4V4B;>.,=
M@?L/I%27/H_R)6?YPC& K0LJ#BM)]"9M3'4>"^O@_KE)*:^+6B$AMG./837E
M*X(0I'1?//E?1PZ@(*-1^ $F[O)&1IXP)\!5R5@ !4FJD-NU:#8/@O8[33<E
MVB$,%Z"@6Q+9"G9D[(%.VC 4:VB98:6VKTYG<C]Z0@D_I&;4QC<0$B.SFC.:
M;9ZSTX[0)HSRL67,R8%O;:@_.#SA^+]I?/=,=-Q/>;A:L3S\B6A77B<4=W),
MAWAO.^.K3V<W1#Y E1WH;K=UH17U%5,L,5RH[WL F\P['G3@!8.##]X;L[9<
M1+[2<K=:#?6/%%RQ$*V:^DY#S"[<[YT,_BHHX!8'?6%.FMQ-3L<;XA\<=H T
MCFNMX\>*0D'?70/XY[6FT#F*V6HM2@*RLB/A+5-CX>/L5!/H8.!R"0D2%C@Y
ML4[)1_Z=F3,7E(,F*Z[*_*H3,2-!U+$KAD#Z@^-!N;*6M#ME"'U,GG:S!!41
M3.T#<>)>#&I2%&)%TVWW'/<B" .IG,J"YF>'9F%0LP.6G+&UVPP8$-=)Y5!!
MDJJM":&(@0>AP]U7DD>,:L.+_[ZL'%\AH6(FPYK)$>SO55N(--1('@=W6GL
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M:5?#UEK@/>E2ZSVI+[. \7X.BG:+BNE?)!>Z1Q"3@Y&0?!7&-F(?XH[)4>.
MYG2#HV[C[X/4Z[,V<KTNKVG@,X7TZ(!QV,^%?J)VM;+,LMLK!(D/=K H$=_E
M'H!#9.@5%K!JF=I*L8Y%/L[AXBOT)^MRY@.HHP[^/#-Y1A12?2;_3G&HM:EH
M,HD;>=HKB&&]5W]H>"J'@/:+8C";$H901;#\LC$RMKMNT<YELW# 3OJ#0"RP
M/2>PW-A$:@_U'!8"I+"J%F]A%-X;U]+^QCGGT81M6Z 3/LE+,?34D*_<^FYK
MD?8Q,E;GN:[6@(]X(&L.F@>J(]-,]&BW9?I#=DHSQST7"3J<:8C]CE#XRQ N
MAI6A;R59I'9+ @-:L K)C!;4*MA'19JM;:A.69'(!(%EMU/2L6MT>I(*#,-4
MX@E!* 3%RMI5Y(Z'$Q'R0I<_SUN>M"L<O3(*B*J>C+'2%^H@(5';5G);F#H<
M%+VK"T%/KA+8:EZ3M!<H;%=_A&*'QJ,2;EP)U]H??H[02)U9##PCFW%"YKB3
M:RI&MBJ\H>3"&!8VZN'T5$=E:KQPFVZZ%.#WZCZ[CU?T5/BN7#D=V'0,94,M
M<*&A'?V;.DEM#*@3.$]J>Q*3W*JCF'=E"RM'BG24O5 4C;;IZ%'B7TXHI[!W
M+B-!5[&OI52ZI#X)K$LQHG>PSRR<5)\G6'<*025:!6=)RAHQ.25XLQ--1C =
MSJ2D,TZH"8-^LG!>="+.SM ^3(>[EX=X3!65B"1:2<@2*?S]^U"6''W4ROE[
MWM:-8@[[B@&KS/1+Y5=:4/SA^CP<\<]\2).4C[A??\K"DT-]IN!''?W@F@RM
M.6D/X2ZA^G[7B741#]J)I+KP@T(_@9%,\15:1Z4#%):5K?RE@O&P R^P)OR3
MAR=@2DQ.CN"^A/^>RG\?R7^_DO]^+?_]1OY[@@\BS!S__>A(5YT(,3Z?=@L?
M+,E;[.$9[^'S#UA\C7W \XY8&[JD8F=,YE(*KBD7AMW&5LWLE$F-Z5ZBHZ"\
M@W6Y7J(YR4H16T[&=P9VJI6'[')Q_$Y@HY%WM2YQ9W/P'ZO_3IDIQ99[%4&\
M@@;%- ([]+T[6+8D!RIV?& XB"$N0'TR[<T*+Y3&Y?@.M4W#] T.WA02@IF:
MA,UE8]-DL17)2U-M1+T^,;!'<(XRUR1P8MU^0JFNE&TB>/6\K <[>:]V]N=S
M6&\#1/CJ $2X8R#"5P<@PIX!$0Z2XNZN=6.+7:,C#F\!1<\P:'3VRXYFS'6V
M3*0(^QH3K-I"7*>"8@R!V+'.+KAT"4[Q>#3L2%0U1-!MZ/#9# A=FAE!PQO&
M01PYQ/CE^7/A8JS=K<Q4T'35H:]Z(E4MPEY3B6N^]BC_E4-!M1VJ5.7UWDM;
MQ8/&2T%T^+.^IJ!N5:[BKHK3#44BJX2I O"FQ()<U0_W&S((7*'F[C6_5=&0
M"+DM1ZY_)^0'B=L#0>F$*07 A]"67L=RO8Q]';.YHO:,G7(66^IM4I44<:Q4
M=1 4<=UBO#IC7VQDN!Y$UA UK%6J)#1@M9*GRILVL \9[RDU<F?<VTZ5")<%
MYO*+F6Z $2TIDOZ1T2Y5!-%)WQ:J7H7!7<7%W3^L*3_,,MWV,S42E<2F5+>9
M2<FS-TAXV543QZ,MQY)A0YBJQSTH%!-PA_O0,0*?=4G^NP\NR:547F54HSL0
M"E)5D0&L?CZQY1DEIPV-1NU;26P5-7.H 774*BH>6V$1PC=#XQJ/M@T,1X )
M+8R!?B^9SEUW4ST =\(_!0FTX]AU9HQME+ +OF1X*CDO"+*0(H-ZZ$,S9CO$
MD8F.KT#6NS!F9HN'V]6B4Y/!IGDU3!J9U>@2\P7:U= L78VRYVZSF<1#I=BD
MX<=8L8:R&3&>XF4'KG#-5!3S;-:FF1R33K3F7EV[]U&3F$N&"\AV%+0!(3+S
M5_GB/"[VK(A97435W8);@X[.11IW3P%M,RIO9%-I$U4MV56O#O)EM$O8X8)<
ME)I.2?<,##.X^H @)5*H>L_";Z&Q<)=+O"LN^6,Y>)I./E009JUS%:/+HY2B
M27""4"5RCY,3T=>"5P)ZGL&05#X+T]C42V.::-(!\!TQ1FX(\LD(%IY.)SB[
M%4\Q.QP_P]MP*0G4-F,TJ+I[BQ5F:AY>BFR%83/X/M^XTJ^"Y;3!;W9]8NI%
M@POG5A&?0MML43+97*>D=:*VD+VSDV@%BDSV@'64X):^,B"!X<*_%@!/C2 \
M%.^H<<S!HBY%LZEJ^4?XB*AS"&\<C& D7//&WBL#K4J2H&S$?L;-@$HA=Y\$
M[/MMCD?T+SHA'-7Q/=T6:N&.6NJSX!Z%+V0#@ 8)G64445GD'*$<IO265W+N
M/$^"G?YM_>;UHJ%M&7A0_;QSOZ6EB\UC\,DG4XMH(H(C:D%O_=JS*H2_DI30
M;8&IKI]S)QE@S"$["PL?CQ18W"(D8@[_JSBYW*8=&/G"X3W\E3PD.W55-CH?
MH<QF7V-.J5]I7B+D6785*1C#I-3(CJ*,NDXY2,((D<.%H=!..H0_.^H=:39)
M_)EV66+)52DL<@BU+MLI7098T6>ATK EV9QWI0)7)-U]C'E8$GV,F:/'8/^9
M 5]D5RP*L-K-.3&N,*YY6E855:2VU42R@FDSR+9AVC%U'6A@2R A16C-6R2:
M/"A$?Q!&^-<E=>PRP?H24I,"T,K"CK<EIAX=G\K6I-1[(@>*F5>&KF+>,\-B
M9CQR ? *;TH!076!U]W.J# ["\9NWP(AUS><NBV0Z\(WX;6'0<!5H%_,U*>(
M4*KX+Z5=S;X@,] BJ[;)'==E3OQG@29*IJ>2W*V%3#<W:1,?)WDPS>,N14_O
M'KV5Y&%'RN<B>O[R<_IWB!?VEM]EK[][]OW9Q;M7SU^?CT>O_@VS_@P^NH"^
M__SNQ_.+Z.R'B_/SG\[?O+N,?GX9P4?16WS\_'+?QOF7KLY?%N1_?'Q"!N]K
MLT#"-T^^<\E'S<'FT;T"PF0NS'TY/W_(!?EL$P$>8R[(H0[''JS3(SJ!KXC+
M3H6LWFEGA%.C$ [8Y7NG"X^K[/ WC!!I-PZV2P#  J[Z)F/>/'?76@Y@R0,=
MCR8A<LHJ<Z<#?M6SM#G2V653R\A'>H?SS')G75][S1#[!$Q58>U@:HWRX?Y(
M<W/VAC$'J7R]L^@ZZ'*D$/U$?':LD-J8H'1%LG)9 4%"5J,H<@,O3BJ93-;=
M8!GKO+HH.4R#366*[$-JE*E&R:- K7KR1-WTWZ/2W/^S?1L(R]<'",L=0UB^
M/D!8]@?"\E\J&>[PUG],M[ZZMXA$[(7S23Z-WE) U469^OK )#FR'F7_.WIS
MS/HZIGQ5>-E4)C?H.!:7I\.)_I&(!F;0$TAA>D1$?O 2+B;:"$P%G34OD6GS
MZP?_1P>+=N3P>;9"H7M$DO0A7D.N:N[#1%W614V1>1R]9):$693,&PGVZC Q
M7:7!! 5, "J)PX73?<ZT4Q%X+2B6P2'P?&/GN<,U'6^+DWLGD$3O>AG:E!0U
M%,L:XB?WW\$OLLKJ>@CH\00MRA'O>47PE^QF'R[-"*OSAY(H*6IO 2NQ^&RP
M/U0O_B/7)?!1"CY!.2DMN$<<4Z'KWWN&=%:J)U%P')\QQL6: 6*0&!2SYAKQ
M5ZI+<<# UZWP_5&+P?/?611=(YQ?C#CT)2.B!9_!;U!PFOZ[!YJA(7)#O)$M
MYYX))0Y%, ." .7[:_.&MP@]439"B4^+RJG3+LE*KVH]&#Z[G?0I=M0%[W01
MNL+"T%+.AS*Q"(PDP379)_FL>I);&^%B#'I&7(*.:T]OB-[0.)H>O%GL#Q62
M+ZO=;S =BH:!ET2]=X3=0M@-N;6I36]8*A 896-BTTO0'!BKE"<;!!H*HTAF
M>1/\K9.%#+AY<MWA8>#,'G__4/!Q/.(.8,F,=4,1<4+[J+W)04H:*$^'+STS
MO$3"[^BX>V[T?#<Z_N$GI"?,Z7<%J*W#"\<7W8ZG; 0!SZ#%9(37FRL:/<2N
MV;%3XX&=XCD[W8[IY4[S"J+JT*E%8#, /7Z#"F!M*](KHX!7( HJWW*S;Z&8
M)N4AX+#:M:'H\L.N]"9!F_-#^RU<5;VYE)3<OK=4=[BD%*4GVP0PZ&&:(QLG
MCN9@>W]F0WE\_(0U;.5GN>#$^;=Y(CXV,#V)I,LE%UIDI:3@#[ /*[UTF^CO
M@HQB56$J3(HJ5&7[,Y=+R[]21>V5@B)4P.P^8@!F+5J52QT#\3=UM+GK,D.<
MTSK#BU!#T(M-F,LL[[#L DX3.@HX*K .(Y:$0<A)!/<RXUM5GC4<0@G)":<?
MZ][)K%RSEAC L*7T4V]R4NM0%)0ZR@KHV$)N?$4>H(N8#?0GQA6\RJJFI6/-
MV#'RI2G3RY.X#$LQFSNNB?!<('E '?1@6B=E#O+A,QO*X^,O23Z\ 9.,+>U^
MUHB4LQW24ATQI4MSB/I9#A]C+(U'+WPM'P%'V^";-R<US-.ZYA\?/P[M(\2#
M%8D%2PUAZ#/!EO;@D(PNI7)CE)W/$%-;3(9NS_"@"BF#6(VD>[4@%7//KM!+
M3O!H@=I5?K-=#W30/#-7@L'P/W 3/VQ+Q]:_+EYY817MH,24S2Y"W#CB;Q(1
M:Z\\J<:5L1F67:"^P^^1U+.? :"MT-"J\BA=MX7F&>XGFJA!>VMJJ$;J1D#
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M]\6_OSG$O^\X_OW-(?Y]B']_YI+A#N^-KP7U%M)$XAW2H:6^].I<W_43)!Q
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MEM*0>7")Y'^PWA6G)=,B<&9.XAFT:CQ;I8[%6OADU;JRLTV@VE="+-!C8H%
MTP E]R0LV*#7;6>VBJ.,E#.;6 *1E"[ 0FH !#6>!@.% @97N828A;RA#S].
ME7*=*W?<%ZLI[;6T8-4OO)WKG_&Y4BVNQ?03+J'O8RR(&PUY#$K\,9<XQ3@$
M)D2Q_ZZ0SI.)<._'^*Z&=\+\Y5GC8@:]A_^><<&0^S2T  ?#$$5M;K25/&%E
M('Q2KT0D[SS.'@W2.;$EUR(M3($_R!_2'(VR*42DO(Y@2^:3(L&,B"+K!FD$
M\PT36NIT 7(ZGB33]/?,3HO_]V!&8<7L*E]\?],!Y4:;J$9#47%[<^,@1-#$
M2[&G/%FMN,<VI@U?/T:&SETG.'8)<Z/GSA +,8'>K.BC(":N4Z@NH[](#1A]
MC7_)-6AP=7]%OSC;HSD$FU^5GP+%@;&R*VT9+#"T4]@J*4[>/#,[J/B0"H52
M@QGKEK@M1_YNHRH#,AE=A&45M-B-(H23-0+V3H<1EWA7V %;<W% LAF-^Z+E
M<K]X/D2'YYVOLG/\%V*"E(Y79/PR.TCK:AN[I]4B47-::&\]IR@#X+H!G87[
M(M"G$':2"(KN3G;G)F<AVZ?[UJ-R^&A2]@&3*':\HVNZ91R0Q -UNF+^-[;X
M<S+)_FQ3; /RD]K#+23#,B=8 Z*BAB6ME)W*'#L+XE6&PM[.E-7E7+M,*]:5
MG6T&<A539S_\"O#L"*T.$7!/?F216 \D(!UC O](XC?1,I"H]D.%PO17H*LC
M]2!=2?K2HZEU(98BPEFU(8,$X^QN)&#JN," WZP_US.@)LX&5$F/\5]F*&"-
MYF(0L9AV40\W\7'BIAZI2+M,T>/S^'IIKLE'4YX(+U#CK*(L%C_!N2E^R-L'
M>+VE5JPK.RQP?H3')=\]=CW-*I^C'H@6BK;63/X%1U]NCW:X>2JU*Y%+J&J/
M#Q@$=%#"/JEP/*,K^-&]@  =7I.:HPC.[ ,-!SA8SY$Z6G/EL.? 'K![U%4]
M7)$/C3J3Y+7UM*_R%,A(D8)*20#]+X2W!^C-TWP$!&7ND"+?B0D#Z?># 2:9
M WD4;GOMICI%K#R$=VM^!C@KS+^:3JE$#C72RF3G^0^/D\GV>#O9@BG^4%:?
MDCW4K7+][804&/O@4Z!^ZR4(N?P^#8(7$:Q@T5 A,&3!6"5_YE Y_V#!6"5"
M50N='Z0";&$*[*#3P"F73L6EO\-@%O-H./L=ROO7&1 B)UM/,3Y4#.X8'W+#
M#!TEO( ;81@!YY:>;Y]N)Q3_00!8Y9[^L0#ZQP12R@6&@("]+8<]DU57>">$
MBI!!AXM^W)&4CE033_+;XC YMW\<+'TK TV[$W<8':(R#4/AZ! ;0 0_=OM;
M3/P]UC?/6:N.'96<WE_G*](?+.\C])4L4>=K<^/SA;Z2%IVO!W',?/T3\RZ)
MT*?K1.B2$Z%/UXG0=2)TQ2W#$GUIPA3M"L= _4OR'NMY?'71314\G)7#$J!!
MEPN X"?/4\#LJV.J=6&8#D!+-1]&03,Z$.'XA>\W&/ ]#4*W+9!F@$-T%Q3$
MVP#\-<!*3I.=Q]M/_M8"(I)P"E4DH^2KP5O"4=JOG(L"([#+$C7^/K %U=7J
M[1J05;?1QC!(UD'%]P8$DZJINJIF/@GX8M$K8@5Y&WS&HYMFP<P7"I@ ;7LL
M<9HS6;P?TK!TJY*B+BCX ;(+1"5B01.K PT0& ;%BJY_5,SKPW^0Q*-RHJ!>
MK2,0285\465SXQW\T&QPAV>*.X>E8@;VA4M72M.&7%D_3$&^)PXE!&5J72^V
M3?"V"/_5&L;C.Q\&L<&O%#Y + 2A-O!$<YTQ$A2$K:L]4XTTM.534DE_:VOI
M/@;4L5!;PV.$@S"B:T6@96$3M1J/UBICL]QSH3XO"OB7FZ>\8G]8*N+-BL1O
M;V]N[-(($VE*P&?"O<-5V5P(W@WF++U?=RD7D6O"F4/ )D$?<R]+KN,J\_G&
M,23K(*NS^!EM^7R5!<;QOAG72+R84<-AL>CC.'RAXZ(4Z"T(_*!\V)EO(_60
M4]P.;U=10%X"];20K (J9%*-H5K[[BO6E9WM'_&$?D/"+$;_]I)_(T3E6#)!
M=TAW+\Z)!J* 330H,;)@%)12W.X+*M("_GR.9@%5""9DT"AY)A?%Q*IT(IF=
M]3I:L:[LL)SRZ:P/.<N2:>9W:_"XZE;(5;MEP>KE BF+F2*$F:"B? %G 7(,
MR)A7;F[X*&M*;P\1#^!38B ,_Q@O4)')(7-=5@MP7;<BSI'0)+*2-GON?$Q,
M%E2=F ,$VL=MDXC+2'5FN%VM,A@B :'U].#--03;>$R08(6A 74$<(C=.4)D
M\8>S3$KO0GDDF$?GO Z:J92IUENZKT-XS;Y)XG*1-NI"( _&PX0@&S['!$HF
M1\E<20]B6STH"_$3YU7 $%2#1R15\1*W=Y]BB?[TB7 :WEA@@!Z^SQ[EA7Y_
MD:P)X2^-)N(P+#(U96T_;#_1Q.:M3XDK2H+G/&V8NQ9*!F#Z:35NDNM0&V?$
M+T-SES2LG? _@(T3+)%_#?GK:&/LM43<^02IA_#^!X"2KKD4D%VQE3 *50AA
M>%:DA7H0N)0_K<_N%>O*#HN'O*;4BK/GA^DUYSW=IG.7QEIQ37W^A-RT!8[4
M3:Y<HP>(OK$!!#K.W27+;:908*'5P)OLR4=LC8#*!I9V!&D->)&VWF$R>B>P
MS1$%/0=BIIQRDNR61P-1ND./*R["8KX&4>;"?[@'"OR *0LDAN(+TJ$+(_?$
M$< C^EE&CG0T?.&PU(UQ@\SK4/35[HDQ4R373;*]6]>7A %IJ/AQE\@,85X-
MG0]OA%*CP'L'[7$O.:YJV%X!NV1L8FW(@ICI@B)ZHUGMWCF:*T,!*1Q"%T4?
M%M6;W;7964)&8J&%9XH$F>Y@OAA<F#N7Y*KLH^9"/;L8YQXNK*]V&['*ZT'>
M#S37/K<5W>1E2:H$[I=OT^(2<H"%VNIT@!JUNE<PJI+7DQFCZ;FP )6C+9)+
MM!I)II:Q9Y;\H0U:66(,KC^K:Z](90B>VD Y87C0BC6W+S.&%;8,-P9G6+2#
M=P]7O$-Q<J6\0[LJ?N5W4]= ZXCN)=<4-RF58U#'L"1" ^T\!I$DG#DK,]KV
M3CS"QQ!#HM0]U*\C?X;<B%TKW ]<B$!^MW[YMK5'@Z%MEZ0VZ24A#E2MH$#:
MY??$_TATX3QF[/:W]@*N'JEP]?;+R5S15 !:(/)>8>H""B<B>40X MR'-/VN
M^,XM7"89W!@8<2Y_ZF#(TH#;&=P@^70EUL 1DZ0ZD"1/V^\X,?,'BPO24*DV
ME80A/I;E@"RI49=:,+!2-2.6_:B,R4MBP38-71"4U+)D^= F=!_EL?A=N&N]
M8>9 9Z#Y#/IJHK=J2Q3$)L*B:YU8"*[2Y@R=N[8[E='>P[!YT8U)(*=1/5+$
MWD'38WR]+E_DLBM>7%+.<,.&\GR7;FC'%R#&ISAFQ"7$3QOJ472S.K5!+9/<
M=2!LJI47QETPRG]=./^US")A.:7:\"PM[-':M_WSL D_K+$)2\8F_+#&)JRQ
M"2MN&999&?R80];.(7"W5Q]\NB7TL\ EJ/$YF4W2:S#)UL), XZ<]8FQ8EW9
M$06>GE17WE0PSB201&UW71)-;44ZUW"]3[$2E"/X!!VY%N6_PE=AF(LO<=0B
M4B0C- 25YXPS3UP>(,+[P/?N0>#X>/MZ4Y] \!<EC66?' JZ%+@L9+2F:KJ+
MERNZ97 A!3C62KPF4<O"^4!X >/$BM+N:EN<7\L0]:L W>I1L0&(VK730Z8M
M&AM#$M"+1W@M"2K-)".P/1D,13:!8*V .$Y1$X69%OUKV<,&6ES(7F(L"P=&
M<E/>$[:QVCF4">,J<1\!" DJ@I:H.XJ,HM%K\EH73,>67HWQRLCTC2)D42LZ
MWP^">T5+]_0%SG&%(^8:-.A!?MW=07*X3$[76=.5[,J.ZD@AU2F5+Y*YX0L@
M$"%T0T .,\ A'H?(&=O!<SGD$49<'XT!#HIECB<98LN#8 B$^;#J!)>^NPR.
M,'[93:[*'",!LX+OEG#IZG*&!+A)&?2! 4H@'C6M#>A886F;!EMLO#U& 44S
M)KF#9#ASF[*Y,=3VY4!V(;34 GSI,FR( AC<H53E>%O2+/2P&='7Y536 6@C
MB"!!<_2J:72$AWG!@6B,8R*"<(0A9S3"I-,"D:S^99ZQ4X#['"-#%U"*-B7<
MD?[%#0Z@LE(.;=AP'9;J*C'&7=:#6T"\ H@\<9I/9A3Y(W,/_.5:Z2#1Z"*V
M;RH+XWXQ3Z[+V0@*<> XT7//+P0,0=QK!4CP/624E_LU,P_BY$(WJ$!'F@Z!
ME#NMU;716[&N[(CZP$E6]QDD"$OCO5L-@RJ]=N?5"<3.!"&\@%4XXO0(68:W
M#.<.A>=D=>%!FAJ,(VK/="S:Z(:<">J^%$C9$V#_%)\(2%6,_'5)B)?).<8I
M*1N4$R]&0Z58S8"<FBD)M0U*B8SGI"Q,]!X<"*-=;2-UT&_./1!Q.%?QYH4"
M.RCF%_--N\T&]L[-"K7VFF<$8X/P-F1$@(2!LYO0#R3EQ7(YF WX+V)XVIF(
MN#L4N0>"V2LP6_09.T8R;A@J==X4N3W0>,"4R:2Z&QKF23(*%]<"?;5<\X26
M61N %>O*CH@$G&2>72/ C08N$.<@^BSVY>'\DG*0K6UPI^[D&SNO?$3GOKN,
M3X$6QBVE@LISW2/*N?M3B 0Q(HZ8_$!E>#HB\9=H6E2/BVK/+RC9@+NA)"0L
M[H$^Y*-'([HR2()E*\+C<QO=1SJD!^;^/LJS6:*E[>;Q^!!46TO=5>MZ\;B@
MEA51CV%3I 82$&F2I#%*\\I46J+8?#@D<A@#HP8:C>%41W#&G@962!)S=T&9
MG%L:R/:/,F]YY<P>F'=(_7BP/5QE.)'B'3 $_CRB:RO%]4VRLN]6KUM_%>0<
MG#4IG"O=@4QBV2?5%!_LCT7:*K,.UY&9E>W*CE 4GT#BS9N),&]%<8K,Z*?Y
MB@/ U!.",BB]S]$JB!P/I>",?@=6'TM\@570W':E,$D#!A:?WDA?%RFZL79>
M/V#JDH3G@CPZ[3.%O\(UCS/?X[+(D,N)VZ805[@5#;+_G<$&Q'M?4:?&4LV)
M)\?RD-%>D]0X\^B!,*)Q+R(YAT5I19OUY]9RQ8SD6Q=F^C%]WC9$-F5O(C(4
M826L# U)*A)W4)V57M/5Q8['>G.O6%?<YJ9*A'?,>W::39-=B(5R^+59%V]W
M&2M^>-:T2GZL%1BM?N[=BN?Q'#,>/ETI:Z-_"HZ&!V5/%9W3Y</;,SP%[1&"
M-\H:>^K_ %GC7T(M83" NA)0CN%KNE#6ST0ZH@O^L$IGP#;##7%N1 ;%]5C_
MCZJA,,Y=L7,L[H%Z7!_+BHC=J!65(3Z?<D'<$/H\@&^CKIO5Y\+K?EEYO4]_
M!TB<+U!/,WIK)A)O,=Q4;DH%VN2[<1%>I,6G:C:9]MF.$TX+..89IH6_[1.!
M/#RU9-E3=#'(Z8,![I-?1C>E:;#\C!W""Y/KH[=$-E1<A9,F 5F<+L8"TS"2
M$P9 &T,*>(4%EPS[@8(_LKFM83'4(Y& L:RZRW3@V5U1Q$& 2=%:<XN@' [U
M\ZST.EA;R3\/SO!L#6=8,ISAV1K.L(8SK+AE6*;_1!5X!^X-DPQ?X[8$E8/;
MDG:!R1T;EQZ.$8RYF@J<"/L7U;+Y<[G=>4+WA/3[U-U']3ZCW=>LI8[JH+O\
MU07"9$J9:Y"7RI[K;PWHN2":,*9%ODL;;NGI#4#14LO9\9&;&VW?UR[R[PD7
M$//H>H]5J+TJ\BF F+$%D&HPL/'MM(;+D>#Q+_,):IQ+E(1\*)XH2-$+F8".
MRR<,#0_I-CLG4BG)F@-H9C:>L"/4(C!;V:ER[;BG6&QT[5-'^I:ZB(7W:0!D
MFS)Y/Y#VJI[[[31"3.U4<I""M357@%MH9J>&3"#@08:86UR&:AB2;TQ(8(7-
M-*RJ+C+ &D-(8!@ZU5Z #;U.F&C2\4U]$ 5(I!6[B\O0 W85V,Z*Q[%H)^H)
MH+>I&"J:!J&A514W*H]A*G7)+X#+ZRR>E3NV%1<+YO$5IC[36C;Q '26ZFE%
MJ=AFO7H+>4%4WB+-PE1G'P =E"'W5&\AA1G)[UU25<=I_S)WOO0;I$_;#O_I
M<SDZ/C;S%(61,(2K'V2Q98E4@IA:%M.YP_!C_H06+T>Y,/!E*6P"Y G)A<+[
MVLN$Q*0& QF P0FF1&N/[D^@HIF&Y)?PL[LI4<,&;C>7*M 0=UZ2UY[GW\".
MM 2 $4B$9/*%C#>IC5(UF@4XM7497KU(?2.UIQ.DPT;S;N)[KU_RJHQ*E.O'
M'_P]6FE&VU:^C&]Q5]./\: \"#?E87E<5-%\F+M5CH&79)\BL-Z+BCGE[?$%
M&U0*<2&L"Z$)_R@)YBK-;,KD4,2@V1HMMN%75-<T1$%-!)M=H?[X4 D<UDY&
M;$R!H9T;6NGK+;B9C!/!LP"_7+0)"*=]$\LS"2(,26 B)A16)@2E%A3=<<C(
M'1W,*%["D@!6C)74;S!CMPYZK%Q7W$:C N53N,X,TCE\UJU__.$-A#GPIVS:
MWX:-!WEC6$XC(&4#]V<R 7\6UX>_(#A'VP@KI%K+0U&^25X%!9A4S"7'&=XH
M)%T48, EZY*\G#GW#FK+D"77@RWX12(WA=Z^^%3T$@\LQNCO0)ACD; 8B__)
M%9,WN#V?KGF55JTK.]M/J;I@SQ3)^V.AF<9+3#H1A:Z_I\48DC\$CBEYRQPA
MAM M0'XG0' V*W(B6X./0 9AH?<,W^TJM("!G07<DD=)-2-)"%OGKX%PT>-B
M!'<ZOL@_SICTJ\HT.>!<)(QA4V4Y-610I<.IK^D+=@Z7A6MN\1[< 7)15:(S
M%2\(<L3D_Y/+FF%6E],A!"7"PG529ZWE9*R(!B#0G,V5#+OI/^I%TI0?0UDW
M*R</T1M&PC9J1B!^FZ#V;=WE?PURA&P,]!?N#G+!TFCVV!5<6W 9;A/+Q2G#
M +^G/-_<$#+N2"OJ0>S%AV56H#CEY0MG6=[O'ORC=Y(<OTK^Z_SD0W)V<K![
M2!8&HH!'R>[1AV1W[^S@^,@][_S@K)L<GR3O3H[W>CV(4"?\$??E@]/] _Q@
M\O+D^/SUF[/DY0?\V[O=DS/WT^O=@Z/3,_S-\=D;]T[\?7=SP_T#?S[HG2:]
MW;TWR=^/CM^[9Q_"U_?=&\YZ1_#<W</##ZYOQPE\X?5);_>LYY[7^R?\.7G7
M.WE[<';6V\>WOGMW>+"'T?3#W??N>.^=].#7+T^/#\_/>O"8\Z.]XZ/] WWN
MYL;!R4GO'\?P+7IO[Y_O3GJGI^Y?.$:GR:MC]P'7;APC> V,&#H+J-CY$%;&
M-RJ?>O!BZ]17K[Q#]_T5R@1T?OW^X M/S5HY]8:N'!QM;KP_.#MR&REY#]OP
M^%6WK7J"8F00]?%43P+#E.A%R%('H>K9:.YK""A,&WHZZ6QZ65:@^"!"%R7J
MJ:1ZJN&1-<RK&N!#R)@"CL9%>?6@P3T^TV@SBW'F\=[=#1*/"Q.4WV$:T*0A
M[_Z"EH3E=Y)4/-M/]HZA/T?_^=W3>S=^>6/.,TI<A<X'?I[,)A-W#4NAY^[0
M/3QP)Q:U^>7!\5EO[\W1\>'QZP_)F^-#&/K3KCOR]K:#,^5LW_3RJ_6LL9I6
MI5E #D]D,-0<\(U)>>DY'<^^O9B4_E+K[W,WS ]_6]%)TA8^^W'EF_ATY5OX
M[.<OW,156MS+[.G+^?,ES40$=;IH@3HM>7Z^UO^OG)'^9IKU4'<10MN^@?%?
M-VMQLWJ/WJ;YZ/E?8;F> 7IFO5Z_[6:]2G__2RS6%1W^=;-6V!58B6C%=R^
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M(]K\[# )0:@?[_T( R^R)(Y@/*MACN0=\KP1W*+AM("QZ#]YR**F])H%&C7
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MX9M<1&7!#^"^2S J6PQ,CY&,<P)O55Y@1!L# 0S7#@.D<4$OO_FI@5R1S57
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M5%)@VJ:,[^!C4 0CXEJM966]#@Y&&2A=(X3,FJ7P5Z>"2_2_XD$UF/N,^XK
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M"SAX!XAY&]"I1:<W/LV9UN#(-:Z.?6[*%-=];>'Z\W@<.I.7+&BP>$7Q0]5
M'/HX;;Z&JW,;^8AE0=L49>U!8NCPIM\GE=GF[L-/>W+,F6 ^X(Y!"!26A&1?
ME^,U]YX=YC&LTY,YPE;V+A #!PP).)TNQM89BZYIG=?"5;O0&3O 4>!'927$
M0V3H<NS"S3_1V4\I8RX1RT=*+[6E41V:I>:\*D+@]JP9,RB1V#XR3N"!0T4(
M&6A0)2,YXI/.)E?C@9AZ<.B4<7EH4(S+)+R*F49LTAN#+.#TF(P"4 7<++0)
M/7#1*B:'5H!>4:[&QEA-4(6DSGW<II=X<D&YM\6X0SZD%48X) AR\K"%9@#^
M$4[P(3\IF4L(3KH718^P"[H.W("#9P+7@[FT9>%8A9_QW4ND!.NW+PU8W#JQ
M[?1%:_;]GC]].LC\;)COTZFZ]!.14KFH4&=T2.&BJ%AE8RH+C[3%.<Z,.IMR
MP6._TIZ?>NQRSH^. /#%#\"I:"(^@&!(\<7*6G#,NP_<?L+)3OY:65"P0L*D
M.H48VU(EI)=3CCO37*T>1!6E8C-BS^+9&K6E]-%C7T$I\](>0W(X67;D-ND4
M);U(%V&%.6.?PC'_$#CO+5SKNYUKO7.M_]U<ZT_$-_XHG-O?W1]V/Q_W]M-X
M9,O5>:4?P!)V7NDE7ND7G5?Z04[&9&H%61#-DEPU E5AITJABE";A.4@O31J
M;W2)E0QF:<4@:% 5QZB,H/.18-[&&HEZ05+:[*Q<#2$R0.L!!JA3@7<,T-=K
M'+"XQ-Z\VJKF4>O^M5+(&B@,1;D:R,+74@I02",7QFLBYUT[Y&ZMS0O]7B1+
MZ>G9U"(CU-.)+IW7&A-9+W,YH@F64X#G/-WAFA<)R"CY!8& 0=TMZEGP99(R
MKSS]GQVX#OD^M.6E[;A2XQEM/],*OZ*'&C.KDVD8K;YE=Z!O1 ^3<<"5NH!9
MQ5AT8T2SQT\@YHJ LU/-"V1=$()=E_$ FDUP"@=8B.S'K1=B]3>@*\H6<I#*
M/"J 7IQ;VU-5GQRAN(!/=J\8TFE%?3IJ,=9ZS)8AOH)RS(_%<A*J*82F2%B$
MZTDEL":J&(\&.X%0YV$UP0R]H0,U. _.C"T);'QJ4QJ!)Q9\>2]4UB,"H)*K
MM>]#">)&0C!K\ATH030)88X..([I;@AA\?<7M__\_=[MO_^Z>%OEV/2$3+ #
M/,&$.<"^^O@R=2SZO1NCMZ_AV82$V6J3Y=S'6X7EH%"K4!9S1:H<;<&A?!V1
M!B:Q>H9!1GCPUH3J@I'<^G\!H=' 9)8IF5.*CWX/QPW?FZL6(;>>W2:V_/KX
MU:<76M[5=2!I_RU[\_YW/I__:9W/OZOV\!",RG?HSM/ P$WI(>LH<)7,[!'I
MS@23Z7YI\2*\6:?CLGS.)J]B+\4PC>-TBFRO63F"G1)Q@]2>P H_&6+Y=OB2
MP>FE23RK:8R(RKH!1YCK9A%1<74I1X#F%(1V&J1H\D^((SZKO(*')M>.[96K
M4=KZ?Z825(T7TB;7@^=Z;H[W*\; :?M:NZEVU]HL-O;UX];KM@03HPYM32[.
M%6-E @Y(II';X7*ORS:T*Q!)L<5^;]!^J/*$OU7I4A&9</EB25%>'$Q#0^2W
ML/YG[8*&*9BL7H0:)X\CA4NSI[;IF_9D/1/N;))GF&*A[+OTOH 5FZ9C1<(9
MBYCHUO?>]*?0")5&:4W8Q"2F"Z-[XP,,56M%:-,_U%>F\H)QZ6@V,0CS^K8O
M-7>!SP_C(+V%=_9%YYWMO+-_-^_L8][:#V@5'H%O^ F)Q8_/P5;[;3M?;.>+
MO84O]N53\<4^Y@/F@:T$5K+XC<#,@<N^;.)[.;>YITK#*"9J,B!,MC'GDG_@
M0!)"N_;@D<Z6*$V:2VUT9@V3@TALZ4YID]Y2=>7"*FI_5+DN(FW*!#0MY3J!
MT2!4VT]VQB-IC((M1K;<HWAG$J\?>CG33N74&:[>J@COU^/ B[\F9(ZBUCWU
MW21Q_X+$5PLC!%V6[$4+AD&KRU>LU@QQN*RIU^55:0JHYNO(YNFO4&,G_P!_
MZ.DMOU"_1QV^HDQYUZGO5L4FZ#)2;*CYWS*=HFX\J1)RS<1L_B=K N:ZAT^2
MI7@1_6A%-<#0JL(9'*BL "QW2)4O#8+\-:6TL_G+T!<4HX?K,ZG4N JP >=C
M@Q>I[%3H'-.TU7%PY(1B+Z I0#$?M\6^^>7-XF*\/?EPMF^1]N2XQJOO*'@J
MK;>0(3MQI@J57P(ASPJ@DY:O:_''ZO>64T>IRQP84$!5#<AYJI)+G:<F;BL0
MB);G^ LF(]Q5<:PX],)&QF%>N 11&YCB55YA/'Y2<&D-+LB.29T3-=28>8]Y
M80!/5WFCA )]E5Q6Z*7"M(RX28:&<I=:4IA$32Q%RTBU:,HUGJ#?:Z8[<%5+
MW4<X<G5%R%E%CBX=54"+.8+KB6;F(LYAM+1-;STD1K74/F.LLZIM*@),RD<T
MP$5>;0A\O63- NBW9Z@8@9A38*2_(C1/0VK!=;OFNAW.["_+>#]@4MG:&LA>
MXX(WKK5'MI)6\(+,ISBH=VIGV>JDDW:]H(]5[HA[L;$<??@UV9=>9A0,K#'U
M4UIUH><C?AMX @>(RQ5ZREV$\#MLY-PVXB5D?0JN[(YP[[20R@DR8SQ%+%7>
M0,7;;2INGU]+RED9TG3"9.!E)H]15O&C^BQV1Z,;;4 B!XN_=>/4'GK,(I>T
MHI4_:%"55,=!25->A2H.12Q@%M0M[R _<HX\9U\_03AZ['@:51ML0)^MM!36
M>Q*Z-]XYK)KGEKK?VU_?W*0N6MN<2C?!5T+"&,J0JLFP;+*>14/*64]GMJN&
MQ:F&4+Q'8W7A5<;BI,*#V0W1A1W;Z-B&MQ)81>:# 52WG*J<-Z;AO:72CB";
M.U2UK_*9*@:4L-E5,%B26,;R(-@5ME))"ZC5R64=G7HK\8*M1E^JD= YTRS#
MMRBG/EXXA&YS0J8VC3^UR:3[#AU%MJM6U.Q2MPYC!($8V1[XWPS/_%!F,D0:
M!&U]+E)_7GMMDI\S&RY- ^;,$)Y@QB\U1FD&A3'^-"IC3UDV@!NSCODV18V!
M&0CXIB07&KK 4@B@$MED?6*5L<$&NC2"Q@T$'#L<JSBRB?]QF(2VR17VO1:X
MS>_/)S&8%<(F6U'2W>[WT(;H4ON1R$@2F$DLU(; ^'N?0#PY/HD_#9O0&5-D
M#$UY ]<!G'>4 1'3<XP,+MZ11+_7L*&V>^Z8RU+F<COTQ<''LZ/C,Q^(T4!;
M^* .&FH+[N*&?YNE7MG#85V'UE@AE(6'S_ _1JC0G^#\Y+L(V;C# &^[?!='
MUPT"$23W-81_*<Q-*H!U8 %.9#)%X ^+0"G\;;]Q$1M8EQMF.X^+^>X#F =8
M['@ BSDXQ>Y".,6=COXOH;N5O8NSC[^_^_CKZ9&XNP%\.EQ 8Q;ZQ)&S]\57
M'SK49/FP;X$H?/E:?,P8XBY.95$N!AC.PP=?BYM AQVT[E$0'^ZB@X]'O]-V
M>G_QR^G>_P-02P,$%     @ C:*.5"\8?4H\#   X"X   H   !E>#DY+3$N
M:'1M[5IM<]LV$OZN&?T'7*[-V#.2+$M-$\NNI[(M-[YQ$D_L7J\?(1*2$),$
M X!6U%]_SRY 2GYI<]=I6E\N22:V2 #[OOOL0@<OKUZ='[9;!R\GXQ/\%/3G
MX.KLZGQR>+ 3?N+M3GQ]</3FY&=Q>?7S^>2[)S-3^)'8[9=>7.E<.?%:+<5;
MD\NB$QYTQ*6R>O8$&['UXK_=MR]R:>>Z& E:VM\7I4Q37<Q']+M7'WQ79GJ.
MU^\JY_5L%1_J(E5$H/_D\.#TS>NK3;+=F<QUMAI]C#"O=?H7%?A\<OBTF+IR
M_V"'#H1B+CZU2%;/%_Y3"G1P=#CYL-!3[=NMO;W>[L'.T>&?)]YG:+%?%^F/
MH_T@O:E,KN?65$7:34QF[$C\_?28_O[![G)^]J^K2;MUI(U7R:( J?E*C(L"
ME!.<]=6SW@OQ2F>9-H5XJ^;:>655*DZT58D7;V8S'%W,Q875"1Z/??=JH;JO
MI+U6_M,XWU^GK4_E>W^=1!?CR_')Y/6XTVX=CSMB7%J=B=U!1PSZ@X%XFJ?2
M+?8%NXBX[2$O34;Q@K//BJ0GMEY+E\KW(UZ[W1%2))DN="*SKO-RKD1JJ[E(
MM4O,C;(KD9B\E,5*I.I&9:8D#RH7TN:29)W3OFS5;LG$ZYNPUX%Y*RJGA"Y$
M(N&;5GBKI,\1D!WA32I70D:W385?2"^T%POI!!:PR^K"&Q"<@2\^5LZM4K0]
MG.T72I253; %[XI4.)DI86;MUJ"SU^]W^OV^<. 1"C:SH).GUKVOS+XC<7+$
MA_,FN8;P'O(W1Y44&;3EJT$/1Y1@G(_ID"12V'5,I2&F3(RIGD H08_&X4.[
MA1.(Q?JMT)#L0XD-)*X1)DDJ*\ $1)%34_G:FM\$:W:$JZ;OZ'PLIH.<]-K-
M2,6T:282>!Z<AHP32$*J(M7TVO4^)Z?__,+X)^7\!5(NHEB6VLLL1B5Y\4\(
M)9DLCI1?B.;M^?FQ@ L*LCX,+<F#NR76<3P@,FY%1>.0GY/./C\O0+9HMT#%
M.>0<DRB5.HKUD+UGUN0PIG;K!$(.L)E!IO"'$CL_Z%QZE:U"[<]C[9\JN -R
ML4JKX#2<+^^X3$R([=9,@75R/X-E=DV3Z!4.[TJYDE/DU^DJ,!B372P+2-6J
M".Q3RB=2A?)KL:(T&]F0?'5I[#7GK>#FJ!]@ 'PI*[,U95TD697RGLHR=[$(
ML1Q(A!JNGRF9-B6,V2+CB?.C[FZ__R4.'K5$' ?K2KU9F]GGIXJ,SYX#QR<'
MU!\\UWY7R8+KHQ1/LY1+^T)ELZ>6?X^EVDJNF( U/K@^/IP:FXO+[E!LG6HX
M]6O3$\/AL#MX-OAFV-]NMTJK;K2I'()JA@6I6&JD8W+@2X6RC2(;PV7R :"A
M %XZ!M?:.:*T1>LB/Y>3X\C--M']ARPJJMB#;[G([_(9J4HR2:(IB!@0%(3T
MI!5L9W;5U/*^9V%;"+XFEB+2<&O6ED@"E!]RF6)= 3%P8JYDP1J6%)B.$DGE
M.AOQM?D<Z*,L,U88P":B-8\KI/4UP36_#VNZ)\907X& ?/!<%EXF,8<PI%PO
MLRJ3(6V9.\*U6[<=HI;UKJ$FQSTQR7":-<@*<*M2!P>CM[^7K1RH%;3,U$M=
MJ!2J62X48.&-U!GEQPZ9*Y)OT.9239V&QP)G'OQXN/"^'.WL+)?+'H3JS<W-
MP<Z/AP0#*4N.1 T.Q&ULT$6OAB1+&A[!CQSH7 *&(KQV@7;;K?&-*BI5RW?I
MI85MAS85IYDQ%A#".+2)<Y51*!Z/!38]?TY4X1F3'.R/!+I+\.=60)$)3/C]
MLHR9N0=E$)/4(,8M*#BJ7)B"I=H:[O:WX9F(H+W=O2_I]E%+= 50P1G.<90I
MZGF0?1%$A?'40X 97Y&[%B'&* 2=PGOJ5(0SF4[@%'4;LKEJ6G'><IOAVL&Q
M-A*@ZJT8MP S4+M6=TFW=G"?10LHCQ#1@$G>X;6#9S)A+%DN=+) W.(_9J!S
MAS4;&L*EJ;*4:%9%)I>SBJ)>&UOGE<W,!6ZL>%_!*C,* #H%IE#V;G;%.2&/
M$I-$_S<X_1(,CUHBI+PQ-=_MUL>')E_&8X]=H@=GHQ^9?*'#NC?\BJ,M5?FF
MG:!8GYD$W4U*);X 3RBQ<Q7;[CCA"E.S=7L26IJ-H1E])("K;**AHE]"^Q.F
M8T@=DC!*3[R2[PP=!FAE R8.2R0W= 2Z.$ER6@+@29! PP3-5S8\GFJ#ISFS
M7TJ_6,H5DCZ-XI#(71P[(6V"EG&^/A\U04E+"?4F9KU2XNVP+U9X[G@ZMZ&$
M#9QKBAIT-PQ-52+K9K!>-:NQ.0!_7-<1BL"5I@DBK\TEC=?N;XDG$QKS ( P
M$E 9A*;ZM75Q,1C#F,M07S(-C7./'%B@26(&[5(#Z]$OHTA0STJ:T=0&]^KP
M)P%EL@C;I9A:):_] FX[7P1D2;UF >T E<VT=73#T 5Z=[_:@9+!B3F0XVL>
MAF+<E79@RIRJK8U %[* #WY'7@G:J2:=,.N>!Z*UH6K&"7REAKIDL&"@1%]#
M8#1&NEN[#8%TB-P31S*:#B&*[IJ@>UE-,XVV*85B5<U_NY5"L6++*110 -6,
M.BY"@=O$/9)FEY(A,4H:8T<Q#$XA.J$%Q#[7T,)# )W#9*"$-(L35 B81@*N
ML'-#&KB1EIHN09YKFG#@JJSSO"K,1HC<GN=2./(L!,9CE@HCK@NS+-@0RI/>
M0\.F:71V4W>2DM];M:B5(4D*"&/]#& ";>$9#9]#JV!F7?P#0$I4"4LUMO86
M"QP')_F4-7/"5E\*_Z.6"#Y\:NQ2VK1[;LPU3^POZ\;5?2GUCUVBT,74%TC<
MMR,RJ2M'@"M+OU">80-GP<#KP83C'!DK*(U%XA3E4H7N8O!\W#32:]@_YKL>
MM-O#88=S25S>;@UV)P^L;V9#ZXW?]&CTA.PK\Y*&!1L<H1$!K_6@]CA CB;!
MT;RB2#@1&<=W/!UT6TX7U,5Q"5'S54 ;H0<I,QKV\&>^14)V"XEW5@$D(!F7
M*C0]+LB"^E'E)3_@STB*L8-Q\7HJ;D1^HXDR%2^LZX3!R:H#SR@JNIVJ:"35
M07H$KG#TF&Z6:^A#=VL\R<5"SLATIX'&\-<MQ:,N:@_7FJ)-<4J,ZE)/:G3(
MZ$MC4Q>Z,@D'B2@BS*<[-9*@XIAH2O;-H[@P8H>[CQ5<.W]@>5/UMK+5]MV7
MY(^ZJ)I-#3<TF$^ <NZ=%G1^[S%,>?=9+E=W']$<[#X+:'[O+=Q\V##E%@^M
M#?<-]<-XOU3 57GL!Z=F30.OY6[=_[)!(MI2-#AD(!Z&EM&Q:Y!6XU8:=MYU
MP4 [."G"8Y:%FP^$+1/]C>@F#P%\<J8(,[EI#7MT09/,T-HW,SM"+-I'0,O(
M1PD:5)@9Q9C?C$?"7S0E(4"C4\518R5_\:*6PZE[L71+$!Y7!D $N@M)TUZE
M"*C8<)ML(Q+<),N;O+P.DY-X!UQ3;%;1<)+F.HIAUY2O>XJ";Z9?FB6T#>P9
M./R([H!5(3^= IR^OH4.B(HDJHKPN]7NVL4G,>MZAF=(>162%9BI,L^N04JP
M@'R)8CY3S4,C"BH;L'^\(P*:7=]RT<2IB=64&QB>WOY&NCB-J86UP_X?FP#J
MTA"15D]IN$4HE;PH\*'8A&$2KH+520]DZDSG.ERX=2A'5YG$\=!+R<,F*E%K
M1T)0+SKK+BI*WVE *%F-Q0QQXG!T)FV3R%7,Q2%GBENW86#=H)VK,R<%$Q5
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M@6Y6(QLC^%4BE@>II8M 79=5>!"^5W3SE*7OQ#J;B8@GU#FF+(%QG=@J6':
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MIE]?X-Z/FWWMDNZJ>/L^;K$,U48B[[$,W'.YR+=8OK[ !:A">O:@^\\!KLE
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M@[W7+E2P-G8/3(]I4T7#56'>SK1X,"GC2K#)%"T2F&GYJ 67D_EJA-BT[Y!
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M5A+!V!K#,\TYNN)5"?S,?'W-3<U%SNZ2VL-TQJM'&E241<81!(9*U.IAR85
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MH3:>_]W:^%^M +^5"B0[NCS"!:DDF&3U("R?+6:[_!S*PSU2.^*_W*0*AS>
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M(ADS,>UYWX;^Q^%IO^^1#^__?D7PU_W']\DY QYWR)F,_+Z8R'?D"TV@0RY
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MO0!U\X_ZL^2\^6'^S(T^\W]02P,$%     @ C:*.5)]*MWS+"P  EI   !4
M  !L:7AT+3(P,C(P-#$R7VQA8BYX;6S-G6%OV[@9Q]\/V'?@?&\VH(YCYW9
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M?^)^N+_48,_\ U!+ 0(4 Q0    ( (VBCE3]:(>FV9L  &2B P *
M      "  0    !E>#$P+3$N:'1M4$L! A0#%     @ C:*.5,_K ^MV1@
MD= !  D              ( ! 9P  &5X-"TQ+FAT;5!+ 0(4 Q0    ( (VB
MCE0(3-)XY"   /T' 0 )              "  9[B  !E>#4M,2YH=&U02P$"
M% ,4    " "-HHY4+QA]2CP,  #@+@  "@              @ &I P$ 97@Y
M.2TQ+FAT;5!+ 0(4 Q0    ( (VBCE3FIZ?7HPL  "$L   *
M  "  0T0 0!E>#DY+3(N:'1M4$L! A0#%     @ C:*.5)T?/Q$,'   8-8
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M40$ ;&EX="TR,#(R,#0Q,E]P<F4N>&UL4$L%!@     *  H 5P(  '-9 0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
